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“p53 family members regulate the Otx1 gene expression in differentiation of breast cancer stem 
cells and in mammary gland development”. 
 
Tp53, Tp63 and Tp73 family members encode for transcription factors which play a key role in 
control of the genome integrity inducing cell-cycle arrest, senescence, apoptosis or cell 
differentiation. They take a part  in cell stress response and in tumor suppression (De Young MP 
and Ellisen LW, 2007).  
Wild type p53 protein is a growth modulator and its inactivation is a critical event in malignant 
transformation (Gasco M, 2002). 
It has been recently demonstrated that p53 has developmental and differentiation functions (Hu 
W, 2008). Indeed an over-expression of p53 in tumor cells induces asymmetrical division 
avoiding a self-renewal of cancer stem cells (CSCs) and promoting their differentiation (Cicalese 
A, 2009). 
In this study 43 human ductal and lobular invasive breast carcinomas have been analyzed for the 
expression of p53, p63, p73 and a pool of non-clustered homeobox genes. The homeogenes play 
a crucial role in embryogenesis, regulating cell differentiation and proliferation (Pagani IS, 
2010). They are expressed in adult mammary gland  and when deregulated, are involved in 
breast cancer (Lewis MT, 2000). 
We demonstrated that the Otx1 homeogene is transcribed in breast cancer, in CSCs 
differentiation and in adult mammary gland development. 
We established that the p53 and p73 proteins directly induce the Otx1 expression by acting on its 
promoter. Otx1 has been described as a critical molecule for axon refinement in corticogenesis 
(Zhang YA, 2002), and its activity in breast cancer suggests a synergistic function with p53 and 
p73 in CSCs differentiation. 
In adult mammary gland development the Otx1 expression is not regulated by p53, but is 
correlated with the expression of Tp73 in lactation and in regression. This suggests that in 
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1 INTRODUCTION  
 
1.1 The homeobox genes 
Homeobox (HB) genes are a family of regulatory genes which encode for transcription factors, 
which play a crucial role in embryonic morphogenesis. Their functions are critical in specifying 
cell identity, in cell differentiation, and in the positioning of the bodily axis during embryo 
development. They were originally identified through mutations that cause segment 
transformation in Drosophila melanogaster, in which a body part or segment is converted to the 
likeness (identity) of another. Since their discovery, more than 200 homolog homeogenes have 
been identified from vertebrates to plants and fungi. In mammals, they play key roles in a variety 
of processes, including central nervous system and skeletal development, limb and digit 
specification, and organogenesis (Lewis MT, 2000). 
HB genes contain a common 180-nucleotide sequence, termed “homeobox”, that encodes for a 
60-aminoacid domain, the “homeodomain (HD)”, responsible for the recognition and binding of 
DNA-specific sequences on the target genes (Pagani IS, 2010). The HD recognizes DNA 
through a region of homology to the “helix-turn-helix” motif present in a group of prokaryotic 
transcription factors: the N-terminal two helices are antiparallel (helix 1 and helix 2), and the 
longer C-terminal helix (helix 3) is perpendicular to the axes established by the first two. It is 
this third helix, the “recognition helix”, which interacts directly with the DNA major groove, 
forming hydrogen bonds (Fig. 1.1) (Wilson D, 1993). The HD mediates sequence-specific 
interactions with DNA responsive elements (REs), primarily those containing a TAAT, TGAT, 
TTAT or TTAC core motif. Many homeoproteins have been shown to function as transcriptional 
regulators, as activators or as repressors, regulating genes involved in embryonic stem cell 
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Figure 1.1. The homeoprotein and the homeodomain. The HB genes contain a 180 bp sequence, called 
“homeobox”, which encodes for a 60 amino acid “homeodomain (HD)”.  The homeodomain recognizes and binds to 
specific “responsive elements (REs)” in the promoter of the target genes, activating or inhibiting their transcription. 
Despite its considerable variation in primary sequence, the three-deimensional structure of the HD has been 
conserved, and corresponds to three α-helices. The helix 3 is the “recognition helix”  which interacts directly with 
the DNA major groove. 
 
Based on sequence homology among their respective HDs, mammalian HB genes are classified 
into two large groups (Coletta RD, 2004). 
The class I share high degrees of identity (>80%) in their HDs, with the first discovered HB gene 
of Drosophila, called Antennapedia. The most representative genes of this group are the HOX 
genes, organized in clusters of minimum nine genes with homologous HDs, aligned on the 
chromosome and arranged as 13 paralogous groups. Their order of expression along the anterior-
posterior axis of the embryo, is collinear with 3’ to 5’ organization of HOX genes in the 
chromosomes, and is regulated in spatial-temporal manner (Coletta RD, 2004). 
The class II comprises diverged HB genes, such as PAX, EMX, OTX or MSX, so called for their 
homologs in Drosophila (paired, empty spiracles, orthodenticle and muscle segment homeobox 
genes, respectively) (Coletta RD, 2004). New isolated and divergent HB genes are continually 
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being identified. Recent indications suggest that these genes constitute as much as 0.1-0.2% of 
the whole vertebrate genome (Abate-Shen C, 2002). 
The two classes of HB genes differ for the sequence diversity within the HD, that contribute to 
their distinct functional properties, generating distinct DNA-binding specificities, and promoting 
unique protein-protein interactions. Functional specificity is also generated by additional 
conserved domains or motifs that occur in particular homeoprotein families (Fig. 1.2) (Abate-
Shen C, 2002). 
 
 
Figure 1.2. Homeoproteins diversity. The distinct classes of homeoproteins show diversity in the primary 
sequence of HD, responsible for specific DNA binding. Additional conserved domains or motif occur in particular 
homeoprotein families, and contribute to generate functional diversity. HOX proteins contain a hexapeptide (HP) 
motif, a short stretch of conserved residues that are responsible for mediating interactions with PBX homeoproteins. 
MSX proteins also have short stretches of conserved amino acids that flank the HD, called the extended HD (EHD), 
although their functions are unknown. PAX proteins contains an additional DNA binding domain, known as the 
paired box. Members of the SIX family have a conserved amino-terminal domain called the Six domain, and LIM 
homeoproteins have two LIM domains, the protein interaction motifs. 
 
The role of HB genes in embryonic development has been extensively investigated since their 
discovery. Boncinelli asserts that the complexity of an organism is measured by the fact that 
genes expressed during embryogenesis are re-activated in the adult organism, with different 
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functions (Boncinelli, 1996). Recent evidences indicate that HB genes are involved in crucial 
biological processes of adult eukaryotic cells, such as control of cell identity, cell growth and 
differentiation, cell-cell and cell-extracellular matrix (ECM) interactions (Cillo C, 2001). The 
homeogenes regulate the proliferation, controlling the cell cycle. The majority stimulate the cell 
cycle, to expand progenitor populations prior to the differentiation, while a subset of HB genes, 
such as Gax1 or HoxA10, inhibits the cell cycle progression and promotes cellular differentiation 
(Fig. 1.3). Several HB genes are also associated with apoptosis during cell remodeling. The cell 
vitality and the phenotype are regulated by extracellular signals, such as cytokines, growth 
factors, hormones, adhesion molecules and ECM molecules, which activate an intracellular 
pathway resulting in the expression of the HB transcription factors. Variations in the acetylation 
state of histone proteins, covering the promoter regions, affect the transcriptional activity of 
specific genes. Interestingly, it has been recently proposed that acetylation/deacetylation may 
regulate transcription of HB genes, like Hox genes (Cillo C, 2001). 
 
 
Figure 1.3. HB proteins have both a positive and negative effect on the cell cycle. HOX11 and SIX1 act at the 
G2-M transition by disrupting the G2 checkpoint, and causing cells to enter mitosis inappropriately. MSX1 up-
regulates cyclin-D1, so preventing cells from leaving the cell cycle and undergoing differentiation. GAX1, on the 
other end, does not promote proliferation, but up-regulates the cyclin-dependent kinase inhibitor WAF1, which 
prevents entry into S phase. 
 
Due to crucial role of the HB genes, mutations occurring in these genes are associated to human 
congenital, somatic or metabolic defects. For example, mutation of HoxA13 causes hand-foot-
genital syndrome, and fusion between nucleoporin gene Nup98 and HoxA9 by chromosome 
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translocation is involved in myeloid leukemia (Cillo C, 2001). Deregulation of homeogene 
expression plays a key role during tumorigenesis. Normal development and cancer share many 
properties: both processes involve alterations in cell proliferation and differentiation, cell death, 
neovascularization, cell motility and invasion. Thus, genes involved in normal development are 
frequently utilized in neoplasia. The deregulated expression of HB genes has been described in 
many solid tumours, in leukemias and lymphomas (Coletta RD, 2004). 
The involvement of the HB genes in carcinogenesis may be classified, based on their expression 
pattern (Fig. 1.4) (Abate-Shen C, 2002). 
HB genes expressed in undifferentiated cells during development, may be re-expressed in 
tumorigenic cells, derived from the same cell lineage. There are many examples, including brain, 
mammary gland and kidney, in which tissue specific Hox genes are over-expressed in tumours 
derived from tissues in which they are normally expressed during development (Abate-Shen C, 
2002). 
On contrary, HB genes that are normally expressed in fully differentiated tissues, are down-
regulated or lost in tumor. Recently, it has been reported that loss of expression of Cdx2 cause 
colon cancer, and that loss of expression of Nkx3.1 is linked to prostate cancer (Abate-Shen C, 
2002). 
Then, HB genes which are not normally expressed in a specific tissue during development, can 
be expressed in tumors derived from this cells. For example, Pax5 is expressed in 
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Figure 1.4. The relationship between HB gene expression and epithelial development and carcinogenesis. HB 
genes that are normally expressed in developing tissues and are down-regulated in differentiation, are re-expressed 
in cancer. Conversely, HB genes that are expressed in differentiated tissues are often down-regulated in cancer 
progression. 
 
The differentiation status of a particular cell types can be considered the result of the balance of 
the expression of some HB genes and the silencing of the other. The gain or loss of HB genes 
promotes tumorigenesis as a consequence of their inappropriate effects on growth and 
differentiation. Although these genes are over-expressed or down-regulated in cancer, they are 
not considered “classic” oncogenes or tumor-suppressor, like p53, but they are defined as 
positive or negative “tumor modulators”. While not necessarily proved, it has been presumed 
that oncogenic activities are produced by wild-type, rather than mutant, homeoproteins. The 
oncogenic potential is not due to the acquisition of new or altered activities, but reflects a wrong 
spatial-temporal extension of their normal functions. Their loss-of-function is not sufficient for 
tumorigenesis (Abate-Shen C, 2002). 
Indeed, it is evidenced the HB genes involvement in tumorigenesis, further studies are required 
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1.2 Otx family 
The OTX proteins, the vertebrate homologues of the Drosophila gene horthodenticle (Otd), 
include an important class of HD-containing transcription factors involved in the induction and 
in the morphogenesis of the neuroectoderm, leading to the formation of the vertebrate central 
nervous system. OTX/Otd proteins, belong to the Paired-like HD family, are characterized by a 
lysine at position 9 of the recognition (third) helix of the HD. The lysine in this position is 
relatively unusual, and confers to the OTX proteins a high affinity and selective binding to 
TAATCC/T sites on DNA (Klein WH, 199). 
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This gene family underwent to gene duplication during vertebrate evolution and probably, like 
other HD protein families, contributed to increase the morphological and functional complexity 
of the vertebrates. Based on OTX-HD similarity, several other OTX-related proteins have been 
identified. Outside of the HD, homologies between OTX proteins may be found in the glutamine 
stretch. This domain is followed by the KXRX1-2KXK domain adjacent to the HD. After this 
there are the highly conserved WSP domain [(S/A)(I/L)WSPA], 45-50 amino acids C-terminal to 
the HD, and an imperfect repeat of an 18-25 amino acid region, containing the highly conserved 
Otx tail domain (D/E)CLDYK(D/E)(Q/P) located upstream to the C-terminal W(K/R)FQVL 
motif  (Fig. 1.5) (Bellipanni G, 2009). 
Based on sequence homologies within the C-terminal domain, Otx proteins can be classified into 
three groups: OTX1/OTX3, OTX2, and OTX5/CRX. In particular, OTX1 and OTX3 show a 
region containing three separate stretches of histidine (HRSs: histidine-rich sites) (Fig. 1.5) 




Figure 1.5. Primary structure of the OTX1 and OTX3 proteins. 
 
 
Otx1 (2p13) and Otx2 (14q22.3) genes play a pivotal role during early and later brain 
development. During brain regionalization, these genes are regulated in spatial and temporal 
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The Otx2 gene. Otx2 (orthodenticle homeobox 2) is required during gastrulation, for anterior 
neural plate specification (Acampora D, Gulisano M et al., 2000). In the mouse embryo, the 
Otx2 gene is transcribed in the epiblast (blastocyst at time of uterus implantation, 4½ days post 
coitum-d.p.c.) (Box 1B). At the onset of gastrulation (5½ d.p.c.), Otx2 is required in the visceral 
endoderm (VE) to maintain its transcription in the epiblast, and to mediate Otx2-dependent 
signals directed from the VE to epiblast (Box 1B-C). From early to late streak stage (7 ½ d.p.c.), 
this signal persists in the VE. At the end of gastrulation (7 ½ d.p.c.), a positive signal from the 
anterior mesendoderm is required for Otx2 transcription in the surrounding neuroectoderm, 
while a negative signal from the posterior mesendoderm, contributes to the positioning of its 
posterior border (Box 1C) (Acampora D, Gulisano M et al., 2000). The neuroectoderm of the 
gastrulating embryo forms the neural plate, that give rise to the entire central nervous system. 
Neural folds arise in the neural plate, appose and fuse to form the neural tube (Box 1D). The 
brain develops from the most anterior region of the neural tube and is divided into three primary 
vesicles: the hindbrain vesicle (rhombencephalon), the midbrain vesicle (mesencephalon) and the 
forebrain vesicle (prosencephalon). The forebrain becomes divided into the diencephalon 
caudally and telencephalon rostrally. Negative signals, contribute to distinguishing between fore-
midbrain and hindbrain, inhibiting the Otx2 expression in the hindbrain. Otx2 is predominantly 
expressed in the telencephalon, diencephalon, mesencephalon, and archicortex, while it is not 
expressed in the adjacent neocortex. Therefore, it might be used as a hippocampal marker in the 
telencephalon (Simeone A, 1998). 
 In the adult, Otx2 expression is present exclusively in the choroid plexus and pineal gland 
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Box1.1.  Mouse embryo development 
 
 
                 
 
Box 1.1.A. Stages from the fertilized egg to blastocyst during mouse embryo development. In zygote, the female 
and male pronuclei are labelled red and blue respectively and the second polar body is present at the animal pole. At 
the 4-cell stage the blastomeres are arranged in a tetrahedral form. At the 8-cell stage all blastomeres are initially 
round, but then they flatten at the process of compaction and undergo apical–basal polarization (shown by blue to 
yellow gradient). At the morula (32-cell stage), the embryo consists of both inside (light yellow) and outside (light 
blue) cells. At the blastocyst, the inner cells form the inner cell mass (yellow), which is surrounded by polar 
trophectoderm (light blue) whereas the mural trophectoderm (darker blue) surrounds the cavity. 1.1.B. At 4 d.p.c the 
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blastocyst reaches the uterus. The inner cell mass forms the primitive endoderm and the epiblast (Epi) (primitive 
ectoderm), which alone gives rise to all cells of the embryo proper. The primitive endoderm forms the visceral 
endoderm (VE), which covers the epiblast and extra-embryonic ectoderm when they become elongated into a 
cylinder at 6 d.p.c. At 6 ½ d.p.c. the gastrulation begins with the formation of the primitive streak at the posterior 
end of the embryo. Mesoderm , definitive endoderm, and axial mesendoderm (AME) precursors arise in the streak 
by 7.0 d.p.c and undergo coordinated morphogenetic movements that leads to their eventual placement in anterior 
positions. 1.1.C. At the pre-streak stage , Otx2 is transcribed in the entire VE and epiblast. As the primitive streak 
progresses, Otx2 expression gradually is restricted to the anterior third of the embryo, and at the late streak stage 
includes all three germ layers. A positive vertical signal (arrows) from the anterior mesendoderm (AME) maintains 
Otx2 expression in the surrounding neuroectoderm. Negative signals (T) deriving from posterior axial mesendoderm 
may contribute to defining the posterior border of Otx2 expression. 1.1.D. The neural plate is formed from the 
ectodermal layer of the gastrulating embryo and gives rise to the entire central nervous system. Neural folds arise in 
the neural plate, appose and fuse to form the neural tube. The brain develops from the most anterior region of the 
neural tube and is divided into three primary vesicles: the hindbrain vesicle (rhombencephalon), the midbrain vesicle 
(mesencephalon) and the forebrain vesicle (prosencephalon). The forebrain becomes divided into the diencephalon 
caudally and telencephalon rostrally. The telencephalon eventually differentiates to become the olfactory bulbs 
anteriorly, the cerebral cortex dorsally and the basal ganglia ventrally. 
 
In order to define the Otx2 role in brain development, the knock-out mouse has been generated. 
Otx2 null embryos die early in embryogenesis, lacking the rostral neuroectoderm, fated to 
become the forebrain, midbrain and rostral hindbrain, and show major abnormalities in their 
body plan (Simeone A, 2002). 
Otx2 is an essential regulator of the identity, extent, and fate of the neuronal progenitors, and 
controls the proliferation and the differentiation of the dopaminergic progenitors. The 
dopaminergic neurons are involved in voluntary movements, cognition, and reward responses, 
and their degeneration is associated with Parkinson’s disease. Therefore, Otx2 might be a 
potential target for cell replacement-based therapeutic approaches in Parkinson’s disease. Otx2 
also controls the identity and the fate of glutamatergic progenitors of the thalamus by repressing 
GABAergic differentiation. Any malfunction of this gene may cause neurogical and psychiatric 
disorders (Larsen KB, 2010). 
Furthermore, Otx2 plays a role in the development and function of the retina, in which it is 
expressed at both prenatal and postnatal stages. It is necessary for the development and 
differentiation of the rods and cones via transactivation of another homeobox gene, the cone-
rode gene (Crx). OTX2 protein was also recently detected in the fetal retina in the pigment 
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epithelium (Larsen KB, 2010). The subcellular localization of OTX2 is important to determine 
the fates of rod photoreceptor and bipolar cells, during their generation, and initial differentiation 
in the neonatal retina. The segregation of postmitotic cells into immature rods and bipolar cells, 
under the influence of various extrinsic factors, such as retinoic acid, is accompanied by the  
OTX2 localization into cytoplasm and nucleus, respectively (Baas D, 2000). 
Recent studies have identified a significant number of target genes downstream of Otx2, up-
regulated or down-regulated by this gene. Most Otx2 target genes fall into one of six functional 
categories: actin/myosin binding proteins; extracellular adhesion molecules; proteases and 
proteases inhibitors; RNA binding proteins; transcription factors; and secreted polypeptides, such 
as gonadotropin-releasing hormone (GnRH), released from a subset of hypothalamic neurons 
which control many aspects of reproduction (Boncinelli E and Morgan R, 2001).  
The OTX2 protein acts as a morphogen, generating a gradient in which sequentially and in 
temporal and spatial manner, other genes are activated or repressed in distinct cells, contributing 
to cell proliferation and differentiation. 
In the action space of morphogen OTX2, in the next time, the Otx1 gene is activated. 
 
The Otx1 gene. Otx1 (orthodenticle homeobox 1) is required for corticogenesis and sense organ 
development. During murine embryogenesis, Otx1 expression is detected first at 8 d.p.c., 
throughout the forebrain and midbrain neuroepithelium. In particular, during cerebral cortex 
development, Otx1 initially is transcribed  throughout the entire dorsal telencephalic 
neuroepithelium; subsequently, towards the stages corresponding to the generations of neurons 
belonging to the deep cortical layers, it is restricted to the ventricular zone. At the end of 
gestation Otx1 expression becomes prominent in the cortical plate, consisting of post-migratory 
neurons of layers 5 and 6. Postnatally, Otx1 is expressed prevalently in a subset of neurons in 
layers 5 and 6 (Simeone A,  1998). 
The development of precisely wired neuronal circuits requires that axons grow to appropriate 
targets and form specific patterns of synaptic connections. In many animals, the emergence of 
the final adult pattern of connectivity is preceded by the formation of transient “exuberant” 
connections. A striking example of exuberance in development is seen in layer 5 neurons, of the 
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cerebral cortex, which extend axonal connections to multiple subcortical targets and then 
eliminate a subset of these projections during early postnatal life. Otx1 is required for the 
elimination of these exuberant projections. In the embryo, OTX1 protein is initially located to 
the cytoplasm of the progenitor cells in the ventricular zone, and remains cytoplasmic up to 
neurons migrate and begin start to differentiate. During the first week of the postnatal life when 
the neurons reach the layer 5 in the cortex, the OTX1 protein is actively translocated to the 
nucleus and is involved in the pruning of long distance axonal projections (Zhang YA, 2002). 
The importance of Otx1 in the development of the neocortex is demonstrated in some human 
pathology. In focal cortical dysplasia, a developmental malformation of the cerebral cortex 
highly associated with epilepsy, the OTX1 protein is expressed in balloon cells. These balloon 
cells are derived from cortical radial glia and not from the ganglionic eminence (Larsen KB, 
2010). 
In the adult, Otx1 is expressed in the choroid plexus of the lateral ventricles, in the ventricular 
zone of the ganglionic eminence, in the hippocampus, and in the cerebellum. Furthermore, Otx1 
is expressed in sense organs: is involved in the formation of the ciliar body, in the anterior part of 
the retina, in the inner ear morphogenesis, and is expressed in the olfactory bulb (Larsen KB, 
2010). 
Postnatally, Otx1 is also transcribed at relatively low levels in the anterior lobe of the pituitary 
gland, where it activates transcription of the pituitary hormones. The pituitary gland is an 
essential regulatory, that integrates signals from the periphery and brain to control the production 
and secretion of hormones involved in growth, reproduction, behavior and metabolism. The 
mature pituitary gland consists of five distinct cell types, each defined by the specific hormone(s) 
production. The cell types found in the anterior lobe are thyrotropes, somatotropes, corticotropes, 
lactotropes and gonadotropes. They produce the thyroid-stimulating hormone (TSH), growth 
hormone (GH), adrenocorticotropic hormone (ACTH), prolactin (PRL), follicle-stimulating 
hormone (FSH) and luteinizing hormone (LH). The OTX1 protein directly binds to the promoter 
of GH, βFSH and βLH genes, activating the production of the respective hormones. The pituitary 
gland and the hypothalamus constitute the main axis of the neuroendocrine system and exhibit a 
remarkable coordination in temporal and spatial events regulating their development and 
differentiation (Acampora D, 1998). 
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Most of what is known about the functions of Otx1 comes from Otx1 null mice. Otx1-/- mice 
exhibit both spontaneous high speed turning and epileptic behavior. The adult Otx1-/- brain is 
reduced in weight and size, and histological analysis revealed that the dorsal telencephalic cortex 
is reduced in thickness, mainly at the level of the temporal and perirhinal areas, where a 40% 
reduction in cell number and a disorganization of cortical layers are detected. An abnormal 
apoptosis is not observed, but a reduction of proliferating cells (about 25%) in the dorsal 
telencephalic neuroepithelium suggests that an impaired proliferation may contribute to the 
cortical abnormalities. Further morphological defects are detected in the eye and inner ear. 
Lachrymal and Harderian glands are absent. The inner ear abnormalities in the Otx1-/- mice 
reflect the Otx1 expression pattern in the lateral canal ampulla, and in a part of the utricle as well 
as in the saccule and cochlea. Interestingly, Otx2 is coexpressed with Otx1 in the saccule and 
cochlea, but not in the components of the superior pars. Lack of Otx1 results in the absence of 
the semicircular canal. In the eye and annexed structures of the Otx1-/- mice, the ciliary process 
is absent, and the iris is thinner. At the prepubescent stage the null mice exhibit transient 
dwarfism and hypogonadism due to low levels of pituitary GH, FSH and LH hormones. 
Nevertheless, Otx1-/- mice gradually recover from most of these abnormalities, showing normal 
levels of GH, FSH and LH pituitary hormones, with restored growth and gonadal function at 4 
months of age. Expression patterns of corresponding hypothalamic hormones, such as the growth 
hormone releasing hormone (GRH), GnRH, and their pituitary receptors (GRHR and GnRHR) 
suggest that, in Otx1-/- mice, hypothalamic and pituitary cells of the somatotropic and 
gonadotropic lineages appear unaltered and that the ability to synthesize GH, FSL and LH, rather 
than the number of cells producing these hormones, is affected (Acampora D, 2000). 
The Otx1-/- null mice are also  anaemic. Recently, Levantini and coworkers reported that Otx1 is 
expressed in hematopoietic pluripotent and erythroid progenitor cells, playing a role during 
haematopoiesis, enhancing stem cell (SC) differentiation. Otx1 is present also in mature cells of 
the erythroid and megakaryocytic pathway in bone marrow (Levantini E, 2003). Mice lacking 
Otx1 exhibit decreased levels of erythroid genes, such as Scl, essential for erythroid 
differentiation, and Gata-1 transcription factors. Scl is a direct transcriptional target of OTX1, 
and OTX1 interacts with GATA-1 to activate the transcription of SCL proximal promoter 
(Martin R, 2004). 
The Otx1 gene is expressed in proliferating cells in embryo and in adult tissues, and it is over-
expressed in tumors. Both Otx1 and Otx2 genes are involved in the pathology of the 
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medulloblastoma, which is the most common malignant in children brain tumors. Their 
expression correlates with clinicopathologic classification. Several studies reported that Otx2 has 
an important role in the tumor development, it is over-expressed in a high percentage (20%) of 
primary anaplastic medulloblastomas suggesting its oncogenetic role. (De Haas T, 2006). 
Similarly, Otx1 but not Otx2, is over-expressed in the nodular/desmoplastic sub-type of  
medulloblastomas and in B-cell Non-Hodgkin Lymphoma (NHL). The NHL represent an 
heterogeneous group of malignancies arising from mature B-cells, recruited in germinal centers 
of secondary lymphoid organs during the T-cell dependent immune response. In lymphoma cells 
OTX1 protein exhibits nuclear distribution, whereas in non malignant B-cells it is prevalently 
localized to the cytoplasm. The over-expression of Otx1 in  tumor cells may alter the gene 
expression profile and cause abnormalities in cell-identity and/or proliferation (Omodei D, 
2009). 
 
1.3 The mammary gland 
The mammary gland, unlike most mammalian organs which develop embryonically with linear 
progression until the maturity, is an organ that primarily forms at puberty, rather than during 
embryogenesis. This growth is characterized by a linear phase (encompassing puberty) and by a 
cyclical phase (encompassing pregnancy), both of which are regulated by reproductive 
hormones. Mammary glands are epidermal appendages, derived from the ectoderm, probably 
evolved from ancient apocrine glands associated with the skin. Their primary function is to 
provide nutrition for the young in the form of milk protein, and fat. However, there are other 
benefits provided by lactation, such as the provision of immune factors that are secreted into the 
milk, which confer protection from infection (Watson CJ and Khaled WT, 2008). 
The adult mammary gland is a complex secretory organ whit a lobulo-alveolar structure, 
composed of two tissue compartments: the epithelium, which consist of ducts and milk-
producing alveolar cells; and the stroma, or connective tissue, which is also called the mammary 
fat pad. The mammary luminal epithelial cells (MECs) are classified in ductal epithelial cells, 
that form the ducts, epithelial structures that transport the milk until the nipple, and in alveolar 
epithelial cells, that compose alveoli, ball-shaped structures with a central lumen that opens to 
the body surface, by the ducts. The alveolar epithelial cells are secretory cells, which undergo 
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functional differentiation in pregnancy to produce milk. The MECs are encased by a mesh-line 
system of basal myoepithelial cells, which are contractile and participate in the delivery of the 
milk. The extensive system of ducts and alveoli, forms a bi-layered structure of simple 
epithelium embedded in the stroma, the main components of which are adipocytes, but 
fibroblasts, cells of the hemopoietic system, immune cells, blood vessels and neurons are also 
present (Fig. 1.6.A) (Hennighausen L and Robinson GW, 2005) (Watson C J and Khaled WT, 
2008). 
The existence of distinct epithelial cell lineages, that are derived from an elusive multipotent 
mammary stem cell (MASC), with capacity of self-renewal and ability to generate differentiated 
cells, has been proposed. Models of how these lineages develop have been defined. It has been 
proposed that the cells forming the epithelial compartment of the mammary gland are derived 
from the MASCs, which have the capacity to self-renewal and give rise to committed epithelial 
precursor cells (EPCs). The progeny of EPCs then becomes restricted to a ductal or alveolar fate. 
The ductal precursor cells (DPs) form myoepithelial cells and luminal cells, the two cell types 
that constitute the ducts. During pregnancy, alveoli are generated from alveolar precursors (APs), 
which give rise to myoepithelial and luminal cells, that differentiate in milk producing cells. The 
alveolar epithelium expands during pregnancy, secrets milk during lactation and undergoes 
apoptosis and remodeling during involution. The epithelial remodeling of the ducts and alveoli is 
due to the presence of the multipotent MASCs and progenitor cells, that are located in the ducts 
(Fig. 1.6.B) (Polkyak K, 2007). 
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Figure 1.6. Hypothetical model of human MASC hierarchy and differentiation. A. Schematic picture of a 
normal terminal duct lobular unit with the putative location of the various stem and differentiated cells. Gray line 
denotes the basement membrane; color of the cell types correlates with than in B. B. Hypothetical depiction of 
MASCs and their various progeny. A bipotential SC gives rise to luminal and myoepithelial cells. The intermediary 
steps and their regulation are largely unknown. ER, estrogen receptor; PR, progesterone receptor; CK14, cytokeratin 
14; MUC1, mucin 1. 
 
In the mouse, numerous experiments demonstrated the existence of progenitor cells, in all stage 
of mammary gland development, that can regenerate a functional mammary gland when 
transplantated into the cleared fat pad of a recipient mouse (Vaillant F, 2007). In the human 
breast, putative mammary epithelial progenitors have been identified using in vitro clonogenicity 
assays as a measure of “stemness”. Specifically, several studies have shown that a subset of 
MECs are able to form colonies in vitro and give rise to both luminal epithelial and 
myoepithelial cells. Similar to other tissue types, such as neural stem cells that in nonadherent 
culture forms neurospheres, cultured MECs creates mammospheres enriched from 
stem/progenitors cells. The mammospheres are able to differentiate along all three mammary 
lineages and to clonally generate N-generations of  mammospheres (Fig. 1.7) (Dontu G, 2003).  
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Figure 1.7. Mammosphere ability to differentiate and self-renew.  
 
During the development, the mammary gland progresses through distinct stages: in the 
embryonic and fetal stage, the mammary anlage (the embryonic primordium of an organ) 
develops; in the neonatal and prepubertal stage, there is an isometric growth;  in the peripubertal 
stage, the gland grows allometrically and ducts elongate and branch; in sexual maturity 
branching continues and alveolar bud form. The final stage involves the process of functional 
differentiation. During pregnancy the lobulo-alveolar structures develops to support lactation, 
and, when nursing ceases, there is an involution of these structures. All the processes are 
hormonally regulated throughout development. Ductal elongation is directed by estrogen (E), 
growth hormone (GH), insulin-like growth factor-I, and epidermal growth factor (EGF), whereas 
ductal branching and alveolar budding is influenced by additional factors such as progesterone 
(P), prolactin (PRL), and thyroid hormone. The effect of these hormones and growth factors is 
influenced by ductal epithelium and epithelial-stromal interactions (Hovey R, 2002). 
 
Human embryonic development and morphogenesis. In all mammals the mammary gland arise 
from a localized thickening of the ectoderm or epidermis. In the human fetus, MECs arise from 
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an ectodermal bud to form clusters, that later represent the areolus of each breast. The milk 
streak is first observed during the 4
th









 week, the mammary parenchyma begins to invade the 
underlying stroma and the mammary disc appear. Further inward growth of the mammary 
parenchyma commences at the 9
th





 week, epithelial buds sprout from the invading parenchyma, followed 




 week that results in the formation of epithelial buds with 





results in 15-25 epithelial strips or solid cords, that eventually give rise to the multiple 
galactophores at each nipple. During the branching process, and up to the 32
nd
 week, the solid 





 weeks of gestation, limited lobulo-alveolar development occurs in association with the 
development of end vescicles composed of an epithelial monolayer. In the 32-week-old fetus the 
periductal stroma has a loose appearance, while in full-term infants the rudimentary lobular 
structures are surrounded by a dense stroma (Fig. 1.8) (Hovey R, 2002). 
 
 
Figure 1.8.  Embryonic development stages of the human mammary gland. 
 
Neonatal and prepubertal development and morphogenesis. The mammary gland of newborns 
contain only rudimentary ducts with small club-like ends that regress within a short time after 
birth (Fig. 1.10.A.a). In neonates this gland grows isometrically before the onset of puberty at 8-
12 years. At this stage the female breast begins to show growth activity both in the epithelium 
and the surrounding stroma (Hovey R, 2002). 
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Peripubertal period. From birth to puberty, the gland remains rudimentary and relatively growth 
quiescent. Several hormonal changes in the body precede the puberty. The female releases FSH 
and LH hormones, induced by OTX1 protein, in a cyclic pattern from the anterior pituitary 
gland. These hormones stimulates the ovaries to synthesize and release female sex steroid 
hormones, estrogen and progesterone. The part of the ovarian cycle characterized by follicular 
growth is dominated by estrogen, while the corpus luteum develops, is dominated by 
progesterone. These ovarian hormones stimulate rapid and invasive allometric ductal elongation, 
driven by growth of structures called “terminal end buds (TEBs)”, a club-shaped terminal 
structures that form at distal ends of the rudimentary ducts, and serve as the foci for the cellular 
proliferation, differentiation and apoptosis. These structures are composed of 4-6 layers of 
cuboidal epithelial cells, and are the sites at which the cells divide at a high rate, advancing the 
progression of the ducts into the fat pad (Fig. 1.9). Both estrogen and progesterone have 
pleiotropic actions in the uterus and ovaries, regulating sexual development. In the mammary 
gland they control ductal outgrowth and alveolar expansion, regulating cell cycle, cell 
proliferation and cellular turnover (Fig. 1.10. b) (Lewis MT, 2000).  
 
Figure 1.9. Terminal end buds. A. High-magnification carmine alum-stained wholemount of a primary duct. The 
bifurcating TEB is in the final stages of forming two new primary ducts with independent TEBs. Three newly 
formed lateral (secondary) side-branches are also present along the trailing duct. B. Schematic diagram depicting the 
salient architectural features of TEBs and their subtending ducts, including their fibroblast-rich stromal collar and 
high mitotic index. The arrow indicates the formation of a new lateral duct. 
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The estrogens (Es) bind to two distinct estrogen receptors (ERs), ERα and ERβ, which are 
encoded by two different genes. Like other steroid receptor, these are members of a large family 
of nuclear receptors, which function as transcription factors when activated by the binding of the 
steroid hormones. Whereas deletion of ERβ has not unfavorable effects on ductal and alveolar 
development, ERα is required for normal ductal elongation and outgrowth during puberty, and 
for pregnancy-mediated alveolar expansion. Instead, progesterone (P) bind to two isoforms of 
the progesterone receptors (PRs), A and B, which display differential activities. These isoforms 
are encoded by two transcript derived from the same gene by different start codons 
(Hennighausen L and Robinson GW, 2005). E and P stimulate cellular proliferation, but cells 
that express ER and PR are not proliferative, suggesting these two hormones stimulate the 
proliferation in an indirect manner. The ER+/PR+ cells, through the bond of estrogen and/or 
progesterone, activate the proliferation in adjacent cells ER-/PR- by a paracrine mechanism 
(Polyak). Analysis of the hormone-receptor status of the MASCs-enriched subset (CD44+ 
CD24- PROCR+ CD10-) revealed that they do not express ERα and PR. Expression of ERα on 
MECs inversely correlates with proliferative activity, invoking a model in which ERα+ cells 
secrete paracrine factors, in response to estrogen stimulation, that modulate the proliferation of 
adjacent ERα- cells. Furthermore, similar studies on the progenitors cells found that a subset of 
luminal progenitors cells express ERα. It is plausible that a hierarchy of stem cells reside within 
mammary tissue and that an immediate descendant of the MASCs express ERα and PR 
(Vaillant). 
Ductal elongation is due also at interaction between MEC and the stroma. Fibroblastic stromal 
cells flank the neck on the TEBs, where there is the pronounced synthesis of extracellular matrix 
(ECM) molecules such as chondroitin sulphate or heparan sulphate. The TEB formation depends 
on the interaction of MECs with proteoglycans, adipocytes, collagen (Hovey R, 2002).  
Pregnancy. The greatest portion of mammary growth occurs during pregnancy and is also 
controlled by hormones. During the pregnancy progress, the adipose cells of the pad are 
gradually replaced by ducts, alveoli (not formed before pregnancy), blood vessels, and 
connective tissue (Hennighausen L and Robinson GW, 2005). Proliferation and maturation of the 
side branches occurs to form alveoli which are lined by functionally differentiated secretory 
luminal epithelial cells responsible for milk production. These milk secretory alveoli are 
localized in clusters which resemble bunches of grapes and are called “terminal ductal alveolar 
units” (TDLUs). The TDLUs contain smaller ducts which link the alveoli and are themselves 
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linked by a network of larger ducts. At least some TDLUs are already present prior to pregnancy, 
although they are not as complex as during pregnancy. The epithelial expansion during 
pregnancy probably consists in a combination between existing TDLUs and the de novo ductal 
and lobular growth, although this is not entirely clarified (Molyneux G, 2007). The mammary 
glands growth until the peak of lactation. Proliferation, differentiation and survival of alveolar 
epithelium, depend on the lactotrophs, as prolactin (PRL), produced by the anterior pituitary 
gland (Fig. 1.10.c, .d and .e). Prolactin mediates its action through PRL receptor (PRLR), a trans-
membrane protein of the class I cytokine receptor family. When PRL binds to its receptor, the 
conformation of the PRLR dimer change activating the associate Janus kinase-2 (JAK2). The 
activated JAK2 phosphorylates the tyrosine residue on STAT5, which become able to bind to 
specific site in the promoter of the genes involved in the milk protein production (Hennighausen 
L and Robinson GW, 2005). 
 
Figure 1.10. Adult mammary gland development. Schematic (Aa-e) and wholemount (Bb-e) presentation of the 
different stages and the  principal hormones that control development. A.a. A rudimentary ductal design within the 
mammary fat pad is visible at birth, which grows at the same rate as the animal until the onset of puberty. b. During 
puberty, the cyclical production of ovarian estrogen and progesterone promotes and accelerates the ductal 
outgrowth. At this stage, TEBs appear. c. In the  mature virgin, the entire fat pad is filled with a regular spaced 
system of primary and secondary ducts. d. Hormonal  changes that occur when pregnancy begins increase cell 
proliferation  and the formation of the alveolar buds. e. During lactation, alveoli are fully matured and the luminal 
cells synthesize and secrete milk components into the lumina. 
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Involution. The last stage of the mammary life cycle involves the removal of the differentiated 
MECs, and the remodeling of the gland to a duct system similar to that in the mature virgin. The 
involution of the mammary gland is triggered by the combination of milk stasis and the fall in 
prolactin levels. Lack of suckling and milk stasis results in a rapid, but reversible induction of 
apoptosis within the differentiated populations of MECs. If the lack of suckling is prolonged, 
PRL levels decline below a threshold level, and apoptosis is accompanied by a tissue-remodeling 
phase involving the induction of matrix-degrading enzymes and inflammatory cell infiltration. 
Once the transition to the alveolar remodeling phase begins, the process of involution cannot be 
reversed. The result of this process is the elimination of all lobulo-alveolar structures leaving 
behind a simple ductal tree (Hovey R, 2002). 
 
1.4 Homeobox genes and mammary gland 
The mammary gland is an excellent model for study the gene expression and their function 
during the development, because it maintains the plasticity to repeated cycles of growth, 
morphogenesis, and functional differentiation at the onset of each pregnancy. Specific regulatory 
molecules able to integrate a variety of signals from the cell’s microenvironment and allow the 
MASCs to progress in a coordinated manner, to ensure the maintenance of cell fate and tissue 
identity, have been identified (Chen H and Sukumar S, 2003). The microenvironment is 
composed of myoepithelial and endothelial cells, fibroblasts, myofibroblasts, leukocytes, other 
cell types, and ECM molecules, which support stem cells (SCs) functions. In the mammary gland 
the SC niche modulates the tissue specificity of the normal breast, such as the growth, survival 
and polarity, and the role of the MASCs, by paracrine signals (Pagani IS, 2010). 
The homeobox (HB) genes appear to be good candidates for the orchestration of this complex 
developmental phenomenon, in which form and function are dynamically intertwined. 
In the normal mammary gland HB genes are involved in ductal formation, epithelial branching 
and lobulo-alveolar development, regulating epithelial proliferation and differentiation, through 
positive or negative cell cycle control (Fig. 1.11). They are controlled in a spatial and temporal 
manner in both stromal and epithelial cells, and they are coordinately regulated by hormones and 
ECM, and by other unknown factors, suggesting that many signaling pathways are involved in 
the HB gene functions. Mammary development is driven by a complex network of hormones 
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acting systemically, and is regulated locally by ECM molecules. If HB genes play a role in 
mammary gland development, it would be very reasonable to propose that HB gene expression is 
linked to primary endocrine regulation and is responsive to ECM changes. Many signaling 
pathways, including those involving the hormones and the growth factors, may be integrate into 
the HB genes networks to systematically regulate mammary gland development. The expression 
of HB genes may regulate the ECM and hormone molecules directly or indirectly, and the 
hormones and the ECM/growth factors may control the HB gene expression, with feed-back 
mechanism. These suggestion have been supported by the presence of potential estrogen 
responsive element (ERE) binding site (5’-GGTCAGCTGAC-3’) in the proximal promoter of 
Hoxc6 gene, by in silico analysis. In addition has been reported that Otx1 and Otx2 bind to the 
responsive element in the promoter of LH, FSH, GH and GnRH genes, and regulate their 
expression in the pituitary gland (Chen H and Sukumar S, 2003). 
The accurate spatial and temporal regulation of HB genes during mammary gland cycle are 
required to ensure proper differentiated state. Misexpression of these genes in mammary cells 
may led to failure of differentiation or uncontrolled proliferation, and therefore contribute to 
cancer initiation or progress. Aberrant expression of the HB genes are found in breast cancer 
cells (see table 1.1) and primary carcinomas (Chen H and Sukumar S, 2003). 
Functional analysis indicate that the HB genes play an important role in cell cycle, proliferation, 
angiogenesis, and metastasis (Chen H and Sukumar S, 2003). 
 
Figure 1.11. Homeobox genes implicated in proliferation in the developing mammary gland. The various 
stages of mammary gland development are depicted along with HB genes implicated . 
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1.5 Breast cancer and cancer stem cells  
Breast cancer is the leading cause of cancer related death in women in the United States and 
Europe. Despite significant advances in the diagnosis and in the treatment of breast cancer, 
several unresolved clinical and scientific problems remain. They are related to prevention (who 
needs it and when), diagnosis (more specific and sensitive methods are necessary), tumor 
progression and recurrence (what causes it and how to predict it), treatment (who should be 
treated and how), and therapeutic resistance (how to predict, prevent, and overcome it). 
Resolving all these problems is complicated by the fact that breast cancer is not a single disease 
but is highly heterogeneous at both the molecular and clinical levels (Polyak K, 2007). 
It is now known that breast cancers can be clustered on the basis of gene expression patterns into 
at least five, and probably more, molecular subtypes (Molyneux G, 2007). 
Luminal A and B tumors have a gene expression pattern resembling normal luminal breast cells. 
Luminal A tumors tend to have higher levels of ERα expression and better prognosis, whereas 
Luminal B tumors have lower levels, or are ERα -, and have a poor prognosis. In the normal 
mammary gland the ER+ PR+ cells are not proliferative, while in the breast cancer this 
correlation is lost. The HER2 tumor group over-express HER2, a member of the epidermal 
growth factor receptor family of receptor tyrosine kinases. The normal breast-like tumor group 
shows a gene expression pattern like the normal breast. This group includes non-epithelial breast 
lesions. Finally, the ERα- PR- HER2- (”triple negative”) basal-like group expresses the basal 
cytoskeletal markers and it is find in younger women and associated with BRCA1 disease 
(Molyneux G, 2007). 
 
Cancer stem cells and breast cancer heterogeneity. The “cancer stem cells (CSCs) hypothesis” 
posits that tumors are derived from mutated stem cells that have retained, or progenitors and 
differentiated cells that have regained, the stem cell properties of cell-renewal (Fig. 1.12). Only 
SCs have the capacity to indefinite self-renewal, whereas lineage-committed progenitor cells 
have lost this capacity, but still show extensive proliferation and differentiation potential (Zucchi 
I, 2008). The initiation of breast cancer is due to genetic and epigenetic transforming events in 
the SCs. Subsequent tumor progression is driven by the accumulation of additional genetic 
changes combined with clonal expansion and selection (Polyak K, 2007).  The longevity of 
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normal SCs increases the risk that these cells, over a lifetime, acquire multiple genetic mutations 
necessary for tumorigenesis. The SCs hypothesis of cancer predicts that tumors contain a small 
number of CSCs, which drive tumor growth, and populations of more differentiated non-
tumorigenic daughter cells, analogous to the transit amplifying and differentiated cells of the 
normal tissue (Molyneux G, 2007). 
 
 
Figure 1.12. The cancer stem cell hypothesis. The cancer stem cell might appear after mutations in specific stem 
cells or early stem cell progenitors. It is also possible that cancer stem cells can be derived from differentiated cells. 
There might be numerous factors in the host microenvironment that trigger the initial steps of tumor formation. 
 
 
Molyneux proposed a model that could explain the diversity of breast cancer, on the basis of the 
cell type mutation. The normal breast epithelium is composed of myoepithelial, ER+ luminal and 
ER- luminal cells, as well as stem/progenitor compartment. This model suggested that if 
mutations occur in the ERα+ luminal cells, the ERα+ tumor type may be generated, while 
mutations in the ERα- luminal cells may give rise to the ERα- tumor type. If mutations occur in 
progenitor able to differentiate into either ERα+ or – luminal cells, they could generate tumors 
with a mix of ERα+ and ERα – cells. Alternatively, basal-type tumors may arise by the 
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transformation of stem/progenitor cell as the result of the accumulation of genetic damage. In 
Furthermore, mutations that occur in differentiated cells can confer SC properties of self-renewal 
(Fig. 1.13) (Molyneux G, 2007).  
 
 
Figure 1.13. A model of the origins of breast cancer subtypes. a. The normal breast epithelium is composed of 
myoepithelial (blue), ER+ luminal (orange/green) and ER- luminal (green) cells as well as a stem/progenitor 
compartment (white). b. Basal like tumors may arise following transformation of a stem/progenitor cell as a result of 
accumulation of genetic damage (hatched nuclei). Luminal tumors may arise from a field of abnormal cells 
generated when stem cells acquire genetic damage without actually transforming. One final genetic lesion in an ER+ 
luminal cell (c) or ER- luminal cell (d) within the field generates a tumor. e. Alternatively, if the first genetic lesion 
in a non-stem cell promotes its self-renewal, mutations could accumulate in a differentiated cell to generate a tumor. 
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Breast cancer progression. The breast cancer involves progression through defined pathological 
and clinical stages. It starts with the ductal hyper-proliferation, subsequent evolution into in situ 
or invasive carcinomas, that may be cause in  a metastatic disease (Fig. 1.14) (Polyak K, 2007). 
Normal breast ducts are composed by the basement membrane and a layer of luminal epithelial 
and myoepithelial cells. Cells composing the stroma include various leukocytes, fibroblasts, 
myofibroblasts, endothelial cells and ECM molecules. In the in situ carcinoma the myoepithelial 
cells are epigenetically and phenotypically altered and their number decreases, potentially due to 
the degradation of the basement membrane. At the same time, the number of stroma cells 
increase. Loss of myoepithelial cells and basement membrane result in invasive carcinoma, in 
which tumor cells invade surrounding tissues and migrate to distant organs, eventually leading to 
metastases. Molecular studies revealed that myoepithelial cells associated with in situ ductal 
carcinoma (DCIS) showed the lost of differentiation markers and the up-regulation of the genes, 
that promote angiogenesis and invasion (Polyak K, 2007). 
DCIS-associated with myoepithelial cells have increased levels of ECM-degrading enzymes, 
such as several metalloproteinases (MMPs), that cause the ductal basal-membrane and ECM 
degradation, correlated to the occurrence of invasive tumors (Polyak K, 2007).  




Figure 1.14. The breast cancer progression. a. Breast cancer is a genetically heterogeneous disease that develops 
along a continuum. The normal breast terminal ductal and lobular unit (TDLU) contains lobules and ducts. Atypical 
ductal hyperplasia (ADH) is a premalignant lesion characterized by abnormal cell layers within the duct or lobule. 
ADH is thought to be the precursor of ductal carcinoma in situ (DCIS), which is a non-invasive lesion that contains 
abnormal cells. With each stage, the risk of developing malignant or invasive breast cancer (IBC) increases. Once 
cells have invaded the stroma, the risk for developing metastasis significantly increases. The lymph nodes are the 
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Microenvironmental factors may play a key role in tumorigenesis. Epithelial-mesenchymal 
interactions are known to be important for the normal development of the mammary gland and 
for the breast tumorigenesis. In vivo and in vitro studies demonstrated that the cells composing 
the microenvironment and the ECM molecules, modulate tissue specificity of the normal breast 
as well as the growth, the survival, the polarity, and the invasive capacity of the breast cancer 
cells (Polyak K, 2007). The microenvironment affects the efficiency of tumor formation, the rate 
of tumor growth, the extent of invasiveness, and the ability of cancer cells to metastasize. In 
carcinomas, the influences of the microenvironment are mediated, in large part, by paracrine 
signaling between epithelial tumor cells and neighboring stromal fibroblasts. Carcinoma 
formation from its earliest stages seems to depend on the ability of tumor cells to recruit and then 
subvert a variety of stromal cells originating from adjacent normal tissue. The most common 
stromal response in carcinoma is termed “desmoplasia”, and it is characterized by pronounced 
changes in the ECM, including increased amounts of collagens, fibronectin, proteoglycans, and 
glycosaminoglycans. The desmoplastic stroma becomes highly vascularized as new blood 
vessels are recruited into the developing tumor mass. Fibroblasts in the stroma can become 
activated by the tumour cells and may secrete angiogenic and invasion-promoting factors 
(Elenbaas B and Weinberg RA, 2001). 
 
1.6 The p53 family 
The p53 protein, discovered in 1979 as the protein interacting with the oncogenic T antigen from 
SV40 virus, is a transcription factor product of a pivotal tumor-suppressor gene Tp53, “the 
guardian of the genome”. The active form of p53 is a tetramer of four identical subunits, 
constitutes by the assemble of two dimers. Due to its tetrameric conformation, p53 is able to bind 
the DNA site containing four repeats of the pentameric sequence motif, called p53-responsive 
element (p53RE), in the promoter of the target genes (Chan WM, 2004) (Bourdon JC, 1997). 
The p53RE sequence is represented by 5’-PuPuPuCA/TT/AGPyPyPy-3’, where Pu is purine and 
Py is pyrimidine. 
p53 activity is promoted by a wide range of stress signals potentially affecting genome integrity 
and proper cell proliferation. When activated, p53 is able to coordinate complex cellular 
responses that lead to cell-cycle arrest, DNA repair, senescence, or programmed cell death 
(apoptosis) (Collavin L, 2010). These effects are predominantly due to p53’s ability to bind 
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DNA through the p53REs that regulate the transcription of genes involved in these process, such 
as p21 (cell cycle arrest), Puma or Scotin (apoptosis). Therefore, p53 prevents the proliferation 
of the genetically abnormal cells and the cancer formation. Mutations in the Tp53 gene has been 
frequently associated with human cancer due to its loss of function (Murray-Zmijewski F, 2006). 
Two Tp53-related genes, the Tp63 and the Tp73, were identified in 1997. The high level in 
sequence similarity between p53, p63 and p73 proteins, particularly in the DNA binding domain, 
allows to p63 and p73 to transactivate p53-responsive genes causing cell cycle arrest and 
apoptosis. However, they are not functionally redundant, and each protein has unique functions 
as determined by the generation of transgenic knockout mice (Murray-Zmijewski F, 2006). 
In addition, p53 gene family members express multiple transcripts variants due to alternative 
splicing and use of different promoters. These isoforms code for several proteins, containing 
different domain, and show tissue-specific expression (Murray-Zmijewski F, 2006). Depending 
on the different regulation of these isoforms, the proteins may play complex roles in the control 
of cell growth, differentiation and development. In particular, the generation of a gradient of 
expression of the different isoforms within the tissue may represent an important signal for the 
spatial and temporal regulation of differentiation (Courtois S, 2004). 
 
p53. The human Tp53 gene consists of 11 exons spanning over 19 Kb (GenBank Accession 
Number: NC_000017) on chromosome 17p13.1 (Murray-Zmijewski F, 2006). Human p53 
protein, a monomer of 53 KDa, can be divided into five domains, each corresponding to specific 
functions. The amino-terminal region contain the acid transactivation domain, which is divided 
into two subdomains (TA1 and TA2) with complementary functions. While the main domain 
(TA1) provides to generic transactivation functions, the second one (TA2) may play a role in the 
selection of specific transactivation targets. The first domain also contains the binding site for the 
mouse double-minute 2 (MDM2), the main regulator of the p53 protein stability. These two 
domains are followed by poly-proline-rich site (PRD) (PXXP) (where P indicates proline and X 
indicates any amino acid), with complex roles of protein-binding site and regulator of apoptosis. 
The central part of the protein contains the DNA binding domain (DBD), in which about 90% of 
the p53 mutations have been found in human cancer. This region is followed by the 
oligomerization domain (OD) consisting of a beta-strand and alpha-helix necessary for 
dimerization. A nuclear export signal (NES) is localized in this domain. The carboxy-terminus 
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domain contains three nuclear localization signals (NLS) and a non-specific DBD that binds to 
damaged DNA, and is involved in the down-regulation of the DB of the central domain 




Figure 1.15. Primary structure of the p53 protein. 
 
The p53 pathway. In normal unstressed cells, the half-life of the p53 protein varies between 6 
and 20 min (Riley T, 2008). The levels of p53 protein are down-regulated by the binding of 
proteins, such as MDM2, COP1, PIRH2 or JNK, that promote p53 degradation via the 
ubiquitin/proteasome pathway (Harris SL and Levine AJ, 2005). A key negative regulator of p53 
is MDM2, which binds to the TA domain of p53, and ubiquitylates the protein, targeting it for 
degradation  in the proteasome. Because p53 transcriptionally activates MDM2, the expression 
levels of p53 and MDM2 are balanced through a negative feed-back loop, which is altered by an 
increase in p53 levels following stresses, such as DNA damage. MDM2 also binds to Tp53 
mRNA, controlling the rate of  translation (Whibley C, 2009). 
In response to a stress signal, the p53 protein is rapidly activated in a specific manner by post-
translational modifications, form a tetramer, and HDM2 polyubiquitylates itself, which results in 
the degradation of HDM2 (Riley T, 2008). The half-life of the protein in the cell increases, from 
6-20 min to hours, and this results in 3-10 fold increase of the  p53 protein concentration in the 
nuclei (Harris SL and Levine AJ, 2005 ). 
The p53 pathway responds to a wide variety of stress signals. These include several types of 
DNA damage: telomere shortening, hypoxia, mitotic spindle damage, heat or cold shock, 
unfolded proteins, improper ribosomal biogenesis, nutritional deprivation, and even the 
activation of some oncogenes by mutations (Riley T, 2008). 
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These stress signals are detected by various “signal mediator proteins”, such as protein kinases, 
histone acetyl-transferases, methylases, ubiquitin and sumo ligases, that activate the p53 protein 
by modifications at different amino-acid residues. Different stress signals can induce 
phosphorylation at the serine and threonine residues, acetylation, methylation, ubiquitination or 
sumolation in the p53 protein. The nature of the stress signal determines the type of protein 
modification and, therefore, the transcriptional programme of p53. For example, gamma-
radiation activates the ATM kinase and the CHK-2 kinase, both of which can phosphorylate the 
p53 protein, while UV-radiation activates ATR, CHK-1 and casein kinase-2, which results in the 
modification of different amino-acid residues on the p53 protein (Harris SL and Levine AJ, 
2005).  
As p53 is activated by these protein modifications, it can be inactivated by phosphatases, histone 
deacetylases, ubiquitinases or even inhibitors of ubiquitin ligases (Harris SL and Levine AJ, 
2005). 
The activated p53 tetramer binds to specific p53REs in the promoter of the down-stream target 
genes, mediating their transactivation. Through protein-protein interactions, p53 can bind to and 
then recruit general transcription proteins, such as TATA-binding protein-associated factors 
(TAFs), to the promoter-enhancer region of p53-regulated genes. Recent experiments have 
shown that p53 can also recruit the histone acetyltransferase (HATs) CBP, p300 and PCAF, that 
acetylate Lys residues of histones in the chromatin of target genes, increasing transcriptional 
activity (Riley T, 2008). 
In some genes, the binding of p53 to its RE results in direct repression of that gene. The p53 
protein recruits histone deacetylases (HDACs), that deacetylates Lys residues of histones in 
chromatin , thereby repressing gene transcription (Riley T, 2008). 
In response to specific signals, p53 activates different pathways that lead to cell cycle arrest, 
DNA repair, differentiation, senescence or apoptosis. In contrast to senescence and apoptosis, 
DNA repair and differentiation do not eliminate cells from the organism, but permit to reverse 
the damage and remove cells from the proliferative compartment. The choice between these 
outcomes in a stressed cell depends of a different transduction pathways  (Fig. 1.16) (Riley T, 
2008). 
 




Figure 1.16. Mechanisms of p53 activation and regulation of downstream target genes. 
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p53 and tumors. In the tumors has been found the loss of function of p53, due to direct or 
indirect  mechanisms. The p53 protein can be inactivated by mutations, or by nuclear exclusion 
or protein degradation (Gasco M, 2002). 
In about 50% of common human cancers, Tp53 remains the most commonly mutated gene, with 
mutations, principally missense, in the DBD (Gasco M, 2002). The p53 mutated protein exert a 
dominant-negative effect toward the wild-type p53, through the formation of heterotetramer 
(Whibley C, 2009). Breast carcinomas, associated with germ-line mutations of Brca1 and/or 
Brca2 genes,  and expressing the mutant Tp53, correlate with more aggressive disease and worse 
overall survival (Gasco M, 2002). 
Germ-line mutations in Tp53 occur in a high proportion of individuals with the Li-Fraumeni 
cancer susceptibility syndrome, which confers an increased risk of breast cancer. This implies an 
important role for p53 inactivation in mammary carcinogenesis (Gasco M, 2002). 
In the cancers lacking Tp53 mutations, p53 function is compromised by other mechanism, such 
as protein degradation or nuclear exclusion. For example, in virus-associated cancers, this may 
occur by direct interaction with proteins encoded by virus, resulting in the retaining of p53 
protein in the cytoplasm, enhancing p53 degradation. Various DNA viruses, such as SV40, HPV 
or adenovirus, encode for proteins that target p53 protein. The E6 viral protein expressed by 
HPV specifically binds to p53 and induces its degradation. This observation explain the rarity of 
p53 mutations in HPV-related cervical cancer (Tp53 website). Nuclear exclusion may be 
exercised by an over-expression of HDM2. This protein is able to bind to the p53 protein and to 
promote the ubiquitination of the C-terminus of the p53 that causes the p53 degradation (Gasco 
M, 2002). 
Other indirect mechanisms can contribute to p53 inactivation. Mutations have been identified in 
up-stream regulators of p53, in its co-activators and in transcriptional target genes of p53. For 
example, ATM kinase, activated by gamma-radiations, phosphorylates p53 on Ser 15, to protect 
DNA from radiation damage. Mutations in ATM, found in ataxia-telangectasia or in T-cell 
leukemia, impair the p53 response to gamma-radiations (Tp53 website). A co-activator of p53 is 
the BRCA1 protein. BRCA1 is phosphorylated, after DNA damage, by ATM, ATR and CHK2 
proteins. Activated BRCA1 associates with the C-terminus of p53 and stimulates transcription 
from p53-responsive promoters. Tumors with mutants BRCA1 are deficient in co-activating 
activity (Gasco M, 2002). 
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p53 isoforms. The different functions of the p53 protein in cell growth, differentiation and 
development are due to the presence of tissue-specific p53 isoforms, able to response to stress 
(Fig. 1.17) (Courtois S, 2004). 
The Tp53 gene is characterized by one promoters upstream to the exon1 (P1), and by an internal 
promoter located in intron 4 (P2). The usage of the distal promoter P1 leads to the production of 
p53 and Δ40p53 isoforms, while the internal promoter P2 regulates the expression of Δ133p53 
isoforms. p53 is the full-length protein (FLp53), while Δ40p53 and Δ133p53 are N-terminal p53 
isoforms (Bourdon JC, 2005). 
Δ40p53 isoform is produced by alternative splicing of the intron 2, or by internal initiation of 
translation using ATG +40 of p53 transcript, that results in the lack of the first TA domain 
(Bourdon JC, 2005). 
Δ133p53 isoform is encoded by the P2 promoter in intron 4. It lacks the TA domains, the poly-
proline-rich site domain, and part of the DNA-binding domain (Bourdon JC, 2005). 
In all the transcripts, the intron 9 can be alternatively spliced to produce three isoform, α, β and 
γ, where β and γ isoforms lack the oligomerization domain (Bourdon JC, 2005). 
In summary the Tp53 gene encodes at least for nine different proteins: p53(α) full-length (the 
wild-type, FLp53), p53β, p53γ, Δ40p53(α), Δ40p53β, Δ40p53γ, ∆133p53(α), ∆133p53β and 
∆133p53γ. 
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Figure 1.17.  Schematic representation of the human Tp53 gene (a) and the human p53 protein isoforms (b).   
 
FLp53 and its isoforms have distinct biochemical activities, and the complex balance between 
FLp53 and the isoforms regulates the cellular fate in response to p53 activation. The N-terminal 
isoforms can have a dominant-negative function on the p53 wild-type and inhibit its function 
(Levrero M, 2000). 
∆40p53 (also named p47 or ∆Np53) contains a part of the p53 TA domain and it can activate 
gene expression through the second TA domain located between amino acids 43 and 63. ∆40p53 
can act in a dominant-negative manner toward FLp53, inhibiting both p53 transcriptional and the 
p53-mediated apoptotic activity, and can modify the p53 cell localization and inhibit p53 
degradation acts by the MDM2 (Bourdon JC, 2005). 
Recently it has been demonstrated that p53 regulates directly the transcription of its ∆133p53 
isoform through specific RE contained within the TP53 P2 internal promoter, and ∆133p53 
protein may participate in a negative feedback loop controlling and inhibiting the p53 functions, 
through formation of heterotetramers (Marcel). In zebrafish the human homolog of ∆133p53, 
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prevents the p53-mediated apoptosis in response to embryonic defects or DNA damage, and 
antagonizes p53-mediated apoptosis and G-1 cell cycle arrest, and can inhibit replicative 
senescence (Aoubala M, 2010). 
In normal breast tissue is detectable the expression of p53/p53β/p53γ, but not ∆N133p53; in 
breast cancer ∆N133p53 is over-expressed, and p53β is less detectable (Bourdon JC, 2005).  
 
p53 knock-out mice. In order to assess the role of p53, mice lacking p53 have been generated 
(Blackburn AC, Jerry DJ, 2002). Mice homozygous for the Trp53 null allele (Trp53-/-) die at 4-6 
month of age, primarily from lymphomas. Mammary tumours are not detected, because the early 
death, due to lymphoma, obscures the mammary tumor development. Trp53-/- mammary 
epithelium was transplanted into cleared fat pads of wild-type mice, demonstrating the formation 
of spontaneous mammary tumors (60%). p53 deficiency can promote mammary tumor formation 
in mice as well as in humans. The tumors formed were moderately to poorly differentiated 
adenocarcinomas, with high levels of aneuploidy. Trp53+/- mice survived much longer than 
Trp53-/-, but they also succumbed to lymphomas, and sarcomas (Blackburn AC, Jerry DJ, 2002). 
A significant proportion (23%) of Trp53-/- female mice die during embryogenesis, or in the 
period between birth and weaning, being subjected to a spectrum of abnormalities. In these mice 
the normal process of neural tube closure fails, leading to exencephaly and subsequent 
anencephaly. In addition, many of these embryos exhibit craniofacial malformations, including 
ocular abnormalities and defects in upper incisor tooth formation (Murray-Zmijewski F, 2006). 
Trp53-/- female mice, but not Trp53 null male mice,  have a significant decrease of fertility (Hu 
W, 2009). 
The p53 protein regulates maternal reproduction in mice, through regulation of leukemia 
inhibitory factor (Lif) gene. LIF protein plays a crucial role in blastocyst implantation. 
Implantation is a critical stage in embryonic development, during which the blastocyst 
establishes a close interaction with the uterine tissues, which lead to the formation of the 
placenta. Increase of expression of Lif gene, regulated by estrogen and p53, is coincident with 
the onset of implantation. Trp53 female null mice have an impaired implantation function, due to 
the decrease levels of LIF protein (Hu W, 2009). 
  39 
 
p63 isoforms. The human Tp63 gene consists of 15 exons, spanning over 270 Kb in the 
chromosome 3q27 (GenBank Accession Number: AC078809, AC117486 and AC063939) (Fig. 
1.18) (Murray-Zmijewski F, 2006). 
The Tp63 gene is characterized by one promoters upstream to the exon1 (P1), and by an internal 
promoter located in intron 3 (P2). The transactivating isoforms (Tap63) are generated starting 
from the promoter P1, while the N-terminally truncated isoforms (∆Np63), lacking the TA 
domain, are generated by the alternative P2 promoter (Murray-Zmijewski F, 2006).  
Altogether, Tp63 expresses at least six mRNA variants which encode for six different p63 
protein isoforms, TAp63α, TAp63β, TAp63γ, DNp63α, DNp63β, DNp63γ, in which α, β, γ 
result from an alternatively spliced C-terminal protein (Murray-Zmijewski F, 2006).  
 
 
Figure 1.18. Schematic representation of the human Tp63 gene (a) and the human p63 protein isoforms (b).   
 
The TAp63 isoforms are able to bind to DNA through p53REs, and activate transcription factors 
of target genes. This activation induces cell cycle arrest or apoptosis (Murray-Zmijewski F, 
2006). However, recent studies indicate that p63 proteins can bind to the DNA through specific 
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p63RE conferring responsiveness only to the p63 protein but not to the p53 protein (Murray-
Zmijewski F, 2006).  
 TAp63 has a role in female reproduction. In response to genotoxic stress, Tap63 induces 
apoptosis of oocytes, having a crucial role in genome protection of female germ line. A more 
recent study established a function of Tap63 in mediating senescence and preventing 
tumorigenesis. In addition, Tap63 has a crucial role in preventing invasiveness and metastasis of 
epithelial tumors by controlling expression of a crucial set of metastasis-inhibitor genes 
(Collavin L, 2010). The ∆Np63 isoforms can bind to DNA through the p53RE and can exert 
dominant-negative effects over p53, Tap63 and Tap73 activities, by either competition for DNA 
binding sites or by direct protein-protein interaction (Murray-Zmijewski F, 2006). 
∆Np63 isoforms directly activate specific gene targets not induced by TA isoforms, since they 
contain a unique 14 amino acid sequence that contributes to the formation of an alternative TA2 
transactivation domain. ∆Np63α is an epithelial progenitor cell marker able to maintain 
epidermal SC self-renewal capacity, promoting cell proliferation and during embryogenesis are 
required for the initiation of the epithelial stratification (Craig AL, 2010). 
 
p63 knock-out mice. Trp63-null mice are alive, but die immediately after birth. The mice show a 
severe phenotype, with defects in the apical ectodermal ridge essential to limb development 
resulting in truncated limbs. In addition, Trp63-/- mice do not have hair follicles, teeth, 
mammary, lachrymal and salivar glands. The skin does not progress past an early developmental 
stage: it lacks stratification and does not express differentiation markers (Fig. 1.19.A-D) 
(Levrero M, 2000). 
The phenotype of Trp63-deficient mice suggests that the primary biological function of p63 
proteins is to regulate development of epithelia and limbs (Levrero M, 2000). 
Recently, germ line mutations of Trp63 are found in humans and cause six rare autosomal 
dominant developmental disease which include: Ectrodactyly Ectodermal dysplasia-Clefting 
syndrome (EEC); Acro-dermato-ungual-lacrimal-tooth malformations (ADULT); Lymb-
Mammary Syndrome (LMS); Hay-Wells syndrome, also named AEC syndrome for 
Ankyloblepharon and Ectodermal dysplasia-Clefting; Split-hand/foot malformations (SHFM); 
Rapp-Hodgkin Syndrome (Fig. 1.19.E) (Murray-Zmijewski F, 2006). 




Figure 1.19. A-D. p63 knock-out mice. p63 knock-out mice exhibit developmental defects (B) and does not 
express differentiation markers (D), as the control (A, C). 
Figure 1.19.E. Mutations of p63 in human disease. Location of p63 mutations described in different diseases. 
These include ectrodactyly ectodermal dysplasia and cleft lip/palate syndrome (EEC), ankyloblepharon ectodermal 
dysplasia-clefting (AEC or Hay-Wells syndrome), split-hand/split-foot malformations (SHFM), limb-mammary 
syndrome (LMS) and acro-dermato-ungual-larimal-tooth (ADULT) syndrome. Mutations are mainly found in the 
DBD for EEC, ADULT and SHFM patients, and in the SAM domain for AEC and LMS patients. Abbreviations: 
DBD, DNA-binding domain; OD, oligomerization domain; PR, proline-rich regulatory region; SAM, sterile a motif; 
TA, transactivation domain; TA2, second transactivation domain; TI, transactivation inhibitory domain. 
 
p73 isoforms. The human Tp73 genes consists of 15 exons spanning over 80 kb (Gen Bank 
Accession Number: AL136528) located in chromosome 1p36.3 (Fig. 1.20) (Murray-Zmijewski 
F, 2006). Tp73 express at least seven alternatively spliced C-terminal isoforms (α, β, γ, δ, ε, ζ 
and η), and at least four alternatively spliced N-terminal isoforms initiated at different start 
codon. Like Tp53 and Tp63, Tp73 can be transcribed from an internal P2 promoter located in the 
intron 3. The TA isoforms are generated by the activity of the promoter upstream of exon 1, 
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while the alternative promoter in intron 3 leads to the expression of N-terminally truncated 
isoforms (∆Np73) lacking the TA domain. Altogether, Tp73 expresses at least 35 mRNA 
variants, which may encode for 29 different p73 protein isoforms. So far, 14 different isoforms 
have been described. In contrast to p63, p73 isoforms can start from different ATG codon (ex2 
p73, ex2/3 p73 and DN’p73) and contain different part of the N-terminal domain, suggesting that 
they can have distinct protein interactions and specific activities (Murray-Zmijewski F, 2006). 
 
Figure 1.20. Schematic representation of the human Tp73 gene (a) and the human p73 protein isoforms (b).  
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Tap73 isoforms, like Tap63 isoforms, are able to bind specifically to the DNA through the p53 
RE and activate transcription of the target genes, involved in the cell cycle arrest and apoptosis. 
These isoforms are able to bind the P2 promoter on the Tp73 gene and activate transcription of 
the ∆Np73 isoforms, in response to genotoxic stresses. The ∆Np73 isoforms bind to the DNA 
through the p53REs and exert dominant-negative effects over the p53, Tap63 and Tap73 
activities, and may bind to specific p73REs directly activating specific gene targets not induced 
by TA isoforms. ∆Np73 is the predominant form in the developing mouse brain and is the only 
form of p73 in the neonatal brain and sympathetic ganglia. ∆Np73 plays an essential 
antiapoptotic role during development, acting as a dominant-negative inhibitor of p53, during the 
normal “sculpting” of developing neuronal system (Zaika AI, 2002). 
TAp73 isoforms represent important mediators of apoptosis in particular following the 
chemotherapy-induced DNA damage. TAp63 is also known to play a role in the female 
oogenesis, in which it is essential to eliminate the DNA damage-oocytes. Tap73 prevents 
genomic stress, and loss of Tap73 during aging may contribute to the decline in oocytes viability 
(Gonfloni S, 2009). 
 
p73 knock-out mice. Trp73 null mice, like p63 null mice, are born viable, but show 
developmental defects including congenital hydrocephalus, hippocampal dysgenesis, due to 
disappearance of Cajal-Retzius neurons, and defects of pheromone detection that lead to lack of 
interest in sexually mature females. In addition to these severe neurogical defects, Trp73-/- mice 
show a generalized pan-mucositis, with consequent microbiological infections, which are 
characterized by massive neutrophil infiltration at the affected sites. The pathogenesis of this 
massive inflammation, however, is not clear, since no major defects of the lymphoid and 
granulocyte populations are present in these mice; this raises the possibility that the 
inflammation and the infections are related to the epithelial barrier dysfunctions, as in cystic 
fibrosis. Interestingly, Trp73-/- mice did not show spontaneous tumors up to 15 months of age. 
(Levrero M, 2000). 
Studies of different tumors types have demonstrated that the p73 gene is over-expressed, like 
p63, rather than mutated or deleted in human cancers. ∆Np73 forms a complex with ∆Np63 
counteracting with TAp73, inhibiting p73-dependent proapoptotic activity (De Young MP and 
Ellisen LW, 2007). 
  44 
 
Structural motifs in p53/p63/p73 proteins. The three members of the p53 family share high 
homology both at the nucleotidic and aminoacidic level (Fig. 1.21). Each contain the TA 
domain, the DBD and the OD. The highest level of homology is reached in the DBD, suggesting 
that the three proteins can bind to the same DNA sequence and transactivate the same promoters. 
The high homology is also at the level the OD, suggesting that members of this family form 
hetero-oligomers as well as homo-oligomers. In addition, p63 and p73, but not p53, contain a 
long C-termini, that contains a sterile alpha motif (SAM), which is a protein-protein interaction 
domain. The SAM domain is a globular domain composed by four α-helices and a small 310-
helix. The majority of the SAM-domain-containing proteins are involved in the regulation of the 
development. Unlike other SAM domains, those present in p63 and p73 do not mediate homo-
hetero-dimerization, indicating that they are important for interactions with other, as not yet 
identified proteins (Levrero M, 2000). An additional post-SAM region known as the TA 
inhibitory domain (TID) has been identified in the p63α and p73α isoforms; its function could be 
the inhibition of the transcriptional activity of both Tap63α and Tap73α through inter- or intra-
molecular association with the TA domain (Fig. 1.22). The presence of TID domain within the 
∆Np63α and ∆Np73α isoforms may allow trans-repression of associated TA isoforms, thereby 
explaining their potent inhibitory effect when bound to DNA as hetero-tetramers composed of 
both ∆N-α and TA isoforms  (De Young MP and Ellisen LW, 2007). 
 
 
Figure 1.21. Percentage of homology between the p53, p63 and p73 domains. The highest degree of homology is 
seen within the DBD. The percentage of DBD homology is higher between p63 and p73, than with p53.  
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Figure 1.22. p53, p63 and p73 isoforms. TAD, transcription activation domain; PRD, proline-rich domain; DBD, 
DNA binding domain; OD, oligomerization domain; TD, tetramerization domain (differs from the OD by the 
existence of an additional C-terminal helix); SAM , sterile α motif; TID, transcription inhibition domain; CTD, C-
terminal regulatory domain.  
 
Interplay between p53/p63/p73 isoforms. The p53 family members interact each other to induce 
the transcription of common target genes, and can regulate the expression each other’s. p53 and 
TA isoforms of p63 and p73, can bind to the P2 promoter of p53, p63 and p73, and induce the 
transcription of ∆N isoforms, that can inhibit the TA isoforms activity with  negative feed-back. 
In head and neck squamous cell carcinoma and in basal-like breast cancer cell line physical 
∆Np63/Tap73 complex that inactivate Tap73 has been demonstrated. In conclusion it is evident 
that during normal development and tissue renewal the ratio of these isoforms leads to cell 
proliferation, survival and differentiation, and down-regulation of this balance is involved in 
tumorigenesis (De Young MP and Ellisen LW, 2007) 
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2 AIM OF THE STUDY 
The aim of the study was to evaluate the correlation between the homeobox gene Otx1 and the 
tumor suppressor proteins p53, p63, p73 and their isoforms, to find new pathways in human 
breast cancer and during mammary gland development. 
In order to verify if the molecular interaction between these genes could be involved in the 
differentiation of breast cancer stem cells, we analyzed their expression in human ductal and 
lobular invasive breast cancer and in LA7 cell lines. The LA7 cells, isolated by Professor 
Dulbecco from a rat mammary adenocarcinoma, show the self-renewal stem cells properties, and 
the capacity to differentiate in all the cell lineages of the mammary gland. They can be used as a 
model to study cancer stem cells and mammary gland differentiation. 
Furthermore, the Otx1, Tp53, Tp63 and Tp73 gene expression was evaluated in adult mice 
during linear and cyclical mammary gland development (pregnancy, lactation, involution), with 




Figure 2.1. Aim of the study. The purpose of the study was to evaluate if p53, p63 and p73 proteins could 
transactivate the Otx1 gene expression, directly binding to the Otx1 promoter, through the p53REs, and was 
demonstrate their involvement in cell differentiation. 
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3 MATERIALS AND METHODS 
 
3.1 Human tissue samples 
Tissues from breast carcinoma, over two centimeters in diameter, and non-neoplastic tissues 
were obtained from 78 women, after informed consent (“Ospedale di Circolo, Varese, Italy”), 
between January 2005 and December 2009. The experimental protocol was approved by the 
Ethic Committee of the Insubria University. We selected 43 ductal and lobular invasive breast 
carcinoma for our studies. All tumors were histologically examined by the anatomo-pathologist 
to confirm the diagnosis, and identify the type and grade, as reported in the results (table 4.1 and 
table 4.4). 
Tumor and non-neoplastic tissues were divided in two parts, one placed in RNA later (Ambion, 
Austin, TX, USA) until RNA extraction, and the other fixed in formalin and embedded in 
paraffin for immunohistochemical analysis. 
 
3.2 Mice and mammary gland tissue 
CD1 mice were from the Charles River Laboratories. Mice were maintained in accordance with 
Italian Ministry of Health according to Art. 12, D-L. 116/92, and European Community 
guidelines. All female mice were deeply anesthetized and sacrificed at 1 month, 8 month of age, 
after 2 weeks of gestation and 2 weeks of lactation, and during mammary gland involution, i.e. 3 
weeks post-lactation. For each analysis were used three mice. 
The samples were examined by anatomo-pathological analysis. 
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3.3 p53-deficient mice 
RNA from p53-deficient mice mammary gland tissues (Donehower LA, 1992) were kindly 
supplied by Professor A. Simeone (International Institute of Genetics and Biophysics, CNR, 
Naples, Italy). 
 
3.4 Cell lines and culture 
3.4.1 MCF7 cells treated with all-trans retinoic acid (ATRA) 
Breast cancer MCF7 cell lines (ATCC, Middlesex, UK) were cultured in Dulbecco’s modified 
Eagle’s Medium (DMEM) supplemented with sodium pyruvate (110 mg/l), L-glutamine (300 
mg/l), sodium bicarbonate (2,2 g/l), gentamicin (50 mg/l) and 5% fetal calf serum (Hyclone 
SH30072). 
ATRA (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 95% ethanol and was used at 
final concentration of 1µM for 24 hours. 
Cells were then harvested in Trizol (Invitrogen, Paisley, UK) for RNA isolation. 
 
3.4.2 Doxycycline (Dox) inducible tet-on/p53, -/p63, -/p73 SaOs-2 cells 
Human osteosarcoma SaOs-2 cell lines (ATCC, Middlesex, UK), with Dox-inducible expression 
of Tp53, TAp63α, ∆Np63α, TAp73α, or ∆Np73α, were generate using the Tet-On Advances 
Inducible Gene Expression System (Clontech, Mountain View, CA, USA) (Fig. 3.1). Cells were 
cultured in a 1:1 mixture of Ham’s F-12/DMEM, supplemented with 10% heat-inactivated, 
tetracycline (Tet) system-approved fetal bovine serum (Clontech, Mountain View, CA, USA). 
The induction of the genes expression, was obtained treating the SaOs2 cells with Dox at 2,5 
µg/ml, for 12, 24 and 48 hours. Cells without induction was used as control. 
Cells were harvested in Trizol (Invitrogen, Paisley, UK)  for RNA and protein extraction. 
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Figure 3.1. Tet-On Advanced system. The Tet-controlled transactivator (Tet-On Advanced) is a fusion protein 
derived from a mutant version of the E. Coli Tet repressor protein, rTetR, which is joined to three minimal 
transcription activation domains from the herpes simplex virus VP16 protein. The PTight promoter is an inducible 
promoter that control the transcription of your gene of interest. It consists of a modified Tet-Responsive element 
(TREmod) containing seven direct repeats of the tet operator sequence, tetO, which is joined to a minimal CMV 
promoter. In the presence of doxycycline (Dox), Tet-On Advanced protein binds to the TREMOD, and produces high-
level transcription of the downstream gene of interest. 
 
Figure 3.2. Map and Multiple Cloning Site (MCS) of pTRE-Tight Vector. pTRE-Tight is a response plasmid 
that can be used to express a gene of interest (in our experiments Tp53, TAp63α, ∆Np63α, TAp73α, or ∆Np73α) in 
the Tet-On Gene Expression Systems. pTRE-Tight contains an MCS immediately downstream of the Tet-responsive 
Ptight promoter. cDNAs or genes inserted into the MCS will be responsive to the Tet-On Advanced protein, after 
Dox administration. 
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3.4.3 LA7 cell lines 
The LA7 cell line, the clonal derivative from the Rama-25 line, was cultured in undifferentiating 
conditions using DMEM (Zucchi I, 2007). 
For differentiation experiments LA7 cells, in confluence, were exposed to 1.8% DMSO for 48 
hours. 
Cells were harvested in Trizol (Invitrogen, Paisley, UK) for RNA isolation. 
 
3.4 LA7 transplantation in NOD-SCID mice 
In according to Zucchi et al. (Zucchi I, 2007), sub-confluent undifferentiated (LA7) and 
differentiated (LA7D: LA7 plus DMSO) cells, were trypsinized, counted and diluted in 1X PBS.  
LA7 and LA7D cells, ranging from 1 cell to 100.000cells, were injected into the fat pads of 
female NOD-SCID mice six weeks old, anesthetized with ketamine/xilazine. Tumor growth was 
monitored three times for week, and visible nodules were measured with a caliper. 
The animals was killed after 63 days of observation. Autopsy was performed to score for 
possible metastasis. 
The tumor removed were used to establish cell lines or fixed in formalin and embedded in 
paraffin for immunohistochemical analysis.  
 
3.5 Mammary tumors and metastasis dissociation 
Tumors and metastasis, generated through LA7 and LA7D injection, were dissociated 
mechanically and enzymatically, as described by Stingl et al. (Stingl J, 1998). 
 
3.6 RNA extraction 
The tissues, from human breast tumors and mice mammary gland, were dissociated mechanically 
and homoginezed with Mixermill Retsch MM301 for 10 minutes at 4°C.  
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The RNA was extracted with RNeasy Fibrous Tissue mini Kit from Qiagen (Valencia, CA, 
USA). 
The RNA from cell lines (SaOs2, MCF7, LA7) was extracted using EuroGold Total RNA Kit 
(Euroclone, Milan, Italy). 
The concentration of total RNA was determined using nanodrop spectrophotometer (Thermo 
Scientific, Wilmington, USA). 
Equal amount (1µg) of total RNA from each sample was reverse transcribed using random 
primers (hexamers), according to the protocol of High Capacity cDNA Archive Kit (Applied 
Biosystems, Foster City, CA , USA). 
 
3.7 Tp53 mutation and polymorphism analysis 
The coding regions of Tp53 was amplified by PCR using the primers reported in table 3.1. All 
the reactions were performed in 25 µl of final volume, with 2.5 µl of 10X buffer, 0.3 µl of 10 
mM dNTPs, 1 µl of 10 µM primer F, 1 µl of 10 µM primer R, 1U/µl of RedTaq DNA 
polymerase (Sigma-Aldrich, St. Louis, MO, USA). 
Using the primers p53-DBD-378F and p53-DBD-1161R, the termocycling conditions consisted 
of an initial denaturation step at 94°C for 3 min, followed by 34 cycles of denaturation at 94°C 
for 1 min, annealing at 58°C for 1 min and extension at 72°C for 1 min, with final extension at 
72°C for 3 min. The length of the amplicon was 800 bp. 
For the p53-148F/p53-539R and p53-1004F/p53-1461R primers, the termocycling conditions 
was of an initial denaturation step at 94°C for 3 min, followed by 34 cycles of denaturation at 
94°C for 30 sec, annealing at 58°C for 30 sec and extension at 72°C for 30 sec, with final 
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                             Table 3.1. Primer sequences for p53 mutational analysis 
Primer Sequence 
p53-148F 5’-GTGACACGCTTCCCTGGATT-3’ 
p53-539R  5’-CAAGAAGCCCAGACGGAAAC-3’ 
p53-DBD-378F 5’-GATGAAGCTCCCAGAATGCC-3’ 




                            The numeration is referred to the p53 sequence accession number NM_000546. 
 
 
The PCR products were purified from gel using the Gen Elute
TM
 Gel Extraction Kit (Sigma-
Aldrich, St. Louis, MO, USA), and were automatically sequenced (Bio-Fab Research, Rome, 
Italy). 
The sequences was aligned with the p53 sequence accession number NM_000546, using 
ClustalW program (EMBL-EBI, www.ebi.ac.uk/tools/msa/clustalw2). 
The mutations and polymorphisms were compared with the p53 databases: we used “swiss prot” 
(www.uniprot.org/uniprot/P04637) for mutations analysis, and “Ensembl” 
(www.ensembl.org/index.html) or “SNP-NCBI” (www.ncbi.nlm.nih.gov/projects/SNP) for 
polymorphisms analysis. 
 
3.8 Quantitative real-time reverse transcriptase PCR (qRT-PCR) 
Quantitative real-time reverse transcriptase PCR (qRT-PCR) was performed with TaqMan and 
Sybr Green technology using the ABI Prism 7000 apparatus (Applied Biosystems, Carsbad, 
California, USA). 
Gene expression analysis was performed using TaqMan® Assays-on-Demand probes (Table 3.2 
and table 3.4). All the reactions were performed in 25 µl of final volume. The PCR reaction mix 
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contained 12.5 µl of TaqMan Universal PCR Master Mix, no AmpErase UNG (Applied 
Biosystems, Carsbad, California, USA), 1.25 µl of Assay-on-Demand (primers and probe), 8.75 
µl of nuclease-free water, and 2.5 µl cDNA. The PCR program consisted in an initial hot start at 
50 °C for 2 min and 95°C for 10 min, followed by 95°C for 15 sec, 60°C for 60 sec, for 40 
cycles. 
Sybr Green assays was performed using the specific primers, designed with “Primer 3” program, 
and then validated. 
All the reactions were performed in 25 µl of final volume. The PCR reaction mix contained 12.5 
µl of Power Sybr Green PCR Master Mix (Applied Biosystems, Carsbad, California, USA), X µl 
primers at specific concentrations (Table 3.3 and 3.5), X µl of nuclease-free water, and 2.5 µl 
cDNA. The PCR program consisted of an initial hot start at 50°C for 2 min and 95°C for 10 min, 
followed by 95°C for 15 sec, 60°C for 60 sec for 40 cycles, and a final stage of 95°C for 15 sec, 
60°C for 20 sec and 95°C for 15 sec. 
All the reactions, using Taq Man and Sybr Green assays, were in triplicate. Human, mouse and 
rat beta-actin (Actb) was used as endogenous control to normalize gene expression levels in the 
relative quantitative analysis, using the 2
-ΔΔCt
 method: 
Ct = number of cycle of exponential fluorescence beginning 
∆Ct = Ct (target) – Ct (endogenous control)  
∆∆Ct = ∆Ct (sample) –∆Ct (calibrator). 
In human breast cancer analysis the calibrator was the non-neoplastic tissue, in mouse mammary 
gland development, the calibrator was the mammary tissue from non-pregnant 1 month old 
female, and in cell lines experiments the calibrators were the LA7 cells, and the cells MCF7 non 
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     Table 3.2- Human ductal and lobular invasive breast cancer primers - Sybr Green technology 
Primers Sequence Concentration Sequence accession 
number 
Otx1 F 5’-ACCCATCCGTGGGCTATC-3’       100 nM NM_014562.2 
Otx1 R 5’-TGTGAACGCGTGAAGGTG-3’ 100 nM  
Tp53 F 5’- CCCCAGCCAAAGAAGAAAC-3’ 50 nM NM_000546 
Tp53 R 5’- AACATCTCGAAGCGCTCAC-3’ 50 nM  
TAp63α F 5’- TTTGAAACTTCACGGTGTGC-3’ 200 nM NM_003722.4 
TAp63α R 5’- TGAGCTGGGGTTTCTACGA-3’ 200 nM  
∆Np63α F 5’- GGTTGGCAAAATCCTGGAG-3’ 40 nM NM_001114980.1 
∆Np63α R 5’- GGTTCGTGTACTGTGGCTCA-3’ 40 nM  
Tap73α F 5’- AACCAGACAGCACCTACTTCG-3’ 40 nM NM_005427.2 
Tap73α  R 5’- CGCCCACCTCATTATT-3’ 40 nM  
∆Np73α F 5’- AAGCGAAAATGCCAACAAAC-3’ 200 nM NM_001126240.1 
∆Np73α R 5’- AGGCTCCGCAGCTAGTGA-3’ 200 nM  
Actb F 5’-CGCGAGAAGATGACCCAGAT-3’            40 nM NM_001101.3 
Actb R 5’-ACAGCCTGGATAGCAACGTACA-3’         40 nM  
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             Table 3.3-  Human ductal and lobular invasive breast cancer assays - Taq Man technology 
Gene Taq Man assay Exon boundary Amplicon length (bp) 
Tp53 Hs 00153340_m1 1-2 81 
Otx1 Hs 00293035_m1 2-3 90 
Tp63 Hs 00978343_m1 7-8 85 
Tp73 Hs 01056231_m1 5-6 65 
Actb Hs 99999903_m1 1-1 171 
         
  
Table 3.4- Rat LA7 primers - Sybr Green technology  




Otx1 F 5’-GCTACCCAGACATCTTCATGC-3’ 300 nM 1-1 NM_013109.1 
Otx1 R 5’-GGCGGTTCTTGAACCAAAC-3’ 300 nM   
TRp53 F 5’-GTTAGGGGGTACCTGGATC-3’ 300 nM 1-1 NM_030989.3 
TRp53 R 5’-CGACTGTGAATCCTCCATGA-3’ 300 nM   
TAp63α F 5’-CAAAGCCTTCTCGCGCTAGCTC-3’ 600 nM 14-14 NM_019221.3 
TAp63α R 5’-TCCGTCCCTTTAGAAACCAG-3’ 600 nM   
∆Np63α F 5’-TACCAGCCCCTATAACA-3’ 600 nM 2-2 NM_001127342.1 
∆Np63α R 5’-GACTGCTGGAAGGACACATC-3’ 600 nM   
Trp73F 5’-CAACAACTGCCCTCTGTCA-3’ 300 nM 11-12 NM_001108696.1 
Trp73  R 5’-CTGTTGAGTATCCCGGAACC-3’ 300 nM   
Actb F 5’-AGGCCCCTCTGAACCCTA-3’ 300 nM 3-4 NM_031144.2 
Actb R 5’-GGGGTGTTGAAGGTCTCAAA-3’ 300 nM   
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Table 3.5- Mouse mammary gland- Taq Man technology 
Gene Taq Man assay Exon boundary Amplicon length (bp) 
Otx1 Mm 00550304_m1 2-3 77 
Trp53 Mm 01731281_m1 1-2 133 
Trp63 Mm 00495788_m1 4-5 64 
Trp73 Mm 00660220_m1 13-14 83 
Actb Mm 01205647_g1 2-3 72 
 
 
3.9 Statistical analysis 
The statistical analysis (Student’s t test and correlation) was performed using the GraphPad 
software (www.graphpad.com/quick.calcs/ttest1.cfm). 
 
3.10 Immunohistochemical assay 
The immunohistochemical analysis was performed on the formalin-fixed, paraffin-embedded 
tumor samples. Three µm sections were mounted on poly-L-lysine coated slides, deparaffinized 
and hydrated through graded alcohols to water. Endogenous peroxidase activity was blocked 
with 3% aqueous hydrogen peroxide for 10 minutes. Antigen retrieval was performed with 
citrate buffer (10 mM, pH 6,0) in a domestic 720 W microwave oven. The sections were 
incubated overnight at 4°C with mouse anti-p53 monoclonal antibody (clone DO-7, Ventana, 
Tucson, Arizona, USA) not diluted, and other sections were incubated with rabbit anti-OTX2 
polyclonal antibody (Chemicon International, Temecula, CA, cat. #AB9566) at a dilution of 
1:2000. This antibody was produced using full length recombinant human OTX2 as immunogen. 
Due to amino acid sequence homology between the OTX1 and the OTX2 proteins, the antibody 
react with OTX1. Since Otx2 mRNA has not been detected in any tumors, we considered that the 
immunoreactivity was due to the presence of OTX1 protein. The sections were incubated with 
Ultravision Detection System kit (Thermo Scientific, Fremont, CA) according to manufacture 
suggestion. The immunoreactions were developed using 0,03% 3,3-diaminobenzedine 
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tetrahydrochloridre (Sigma-Aldrich, St. Louis, MO, USA), and nuclei were counterstained with 
Harris’ hematoxylin. 
As controls we use tissues with or without the pertinent antigen, omission of the primary 
antibody and substitution with a non-immune serum at the same dilution. 
 
3.11 Protein extraction from SaOs2 cell lines and western-blotting  
SaOs2-inducible cells were harvested and lysed with lysis buffer, containing 50 mM Tris-HCl 
pH 7.5, 250 mM NaCl, 50 mM NaF, 1 mM EDTA pH 6 and 20% Triton-X 100, at time zero or 
after 24, and 48 hours from the addiction of Dox. Protease inhibitors (Sigma-Aldrich, St. Louis, 
Mo, USA) and 1 mM DTT (Sigma) were addicted. The total lysated proteins were separated by 
SDS-PAGE and transferred into PVDF membranes. Blot were performed using standard 
procedures. The membranes were then incubated with monoclonal anti-OTX1 (Abcam, 
Cambridge, MA, USA) at dilution of 1:200, and with polyclonal anti-p53 (clone DO-1, Santa 
Cruz, CA, USA) at dilution of 1:500. Goat anti-actin (C-11, Santa Cruz, CA, USA), at dilution of 
1:1 .000, was used as loading control. 
Proteins were detected with electochemiluminescence (ECL). 
 
3.12 Chromatin immunoprecipitation (Chip) assay 
12x10
6
 SaOs2 cells were cross-linked for 10 min, in a solution containing 1% formaldehyde. 
Cross-linking was stopped by replacing the solution with 0.125 M glycine for 5 min at room-
temperature. After washing with ice-cold PBS, cells were harvested in lysis buffer (50 mM 
Hepes-KOH pH 8.0, 1 mM EDTA, 140 mM NaCl, 25% glycerol, 0.5% NP-40, 0.25% Triton X-
100), plus protease inhibitors. Nuclei were collected by centrifugation and re-suspended in 
washing buffer (10mM Tris-HCl pH 8.0, 1 mM EDTA, 200 mM NaCl), plus protease inhibitors. 
After centrifugation, the nuclei were re-suspended in 1,8 ml ChIP Dilution Buffer (0.01% SDS, 
1.1% Triton X-100, 1.2 mM EDTA, 0.0167M Tris-HCl, 0.167 M NaCl), plus 200 ml SDS lysis 
buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl pH 8.1). 
Cell lysated were sonicated in order to obtain chromatin fragments of ~700 bp. After 
centrifugation at 13 000 rpm for 10 min to remove any cell debris, total proteins (cross-linked to 
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DNA and not) were pre-cleared with protein G agarose/salmon sperm DNA (Upstate, 
Charlottesville, VA, USA) for 1h at 4°C, in a ratio 50 µg/µl. Then, the pre-cleared extracts were 
incubated with 3µg polyclonal antibody anti-p53 (DO-1, Santa Cruz, CA, USA). 
The negative control was incubate with 3 mg of mouse anti-IgG1k (BD, Franklin Lakes, NJ, 
USA) overnight at 4°C, followed by incubation with protein G-agarose/salmon sperm DNA (40 
µl) for 3 h at 4°C. 
The immuno-complexes were washed twice with low-salt wash buffer (0.1% SDS, 1% Triton X-
100, 2 mM EDTA, 20 mM Tris-HCl, 0.15 M NaCl), twice with high-salt wash buffer (0.1% 
SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, 0.15 M NaCl), then once with LiCl salt 
wash buffer (1 mM EDTA, 10 mM Tris-HCl, 0.25 M LiCl, 1% NP-40, 1% deoxycholate), and 
twice with TE buffer. 
The immuno-precipitates were extracted, twice using 250 µl of IP elution buffer (1% SDS, 0.1 M 
NaHCO3). The total eluates (500 µl) were pooled by adding 20 µl of 5 M NaCl, and incubated at 
65°C over-night to reverse the formaldehyde cross-linking. DNA fragments were purified from 
proteins, using phenol-chloroform extraction and ethanol precipitation. Then they were dissolved 
in 30 µl of sterile water. 
DNA samples were analyzed with 25 cycles of PCR to amplify Otx1 promoter sequence. The 
termocycling conditions used for amplification consisted of an initial denaturation step at 94°C 
for 4 min, followed by 25 cycles of denaturation at 94°C for 35sec, annealing at 61°C for 35 sec 
and extension at 72°C for 2 sec, with final extension at 72°C for 3 min. In table 3.6 are reported 
the primers used for Otx1 amplifications. 
 
Table 3.6. Primer sequences for PCR analysis of the samples after CHIP 
Primers Sequence 
5’p53RE-F 5’- TTCTCCTC TCCTCACCCAGC-3’ 
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3.13 Luciferase assay 
Otx1 promoter with 3’p53RE was cloned into pGL3 Luciferase (Luc) Basic Vector (Promega, 
Madison, WI, USA). 
Luc assay was performed by co-transfecting pGL3-OTX1 with increasing amounts of 
Dox/inducible p53 expression vector, from a ratio of 1:1 to 1:10, in the SaOs2 cells. We used 
Lipofectamine 2000 transfection reagent (Invitrogen, Paisley, UK) following the manufacture 
instructions. 
Luciferase activity were measured using the Dual-Luciferase Reporter Assay System (Promega, 
Madison, WI, USA). Light emission was measured over 10 sec using OPTOCOMP I 
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4 RESULTS 
4.1 Tp53 mutation and polymorphism analysis 
A pool of 33 invasive human breast cancer (30 ductal and 3 lobular ) was sequenced to identify the 
presence of mutations in the Tp53 gene (Table 4.1). We found mutations in the p53 DNA binding domain 
in 3 breast cancer samples with a frequency of 9,1% versus 20% reported in literature (Borresen-Dale AL, 
2003). The mutations in heterozygous state were  p.193 H>R, p.238 C>F and p.195 I>T. 
In 16 out of 33 (51.5%) tumors we found the polymorphism R72 (c.412 G) in homozygous state (Fig. 
4.1.A). 14 out of 33 (39.4%) carried the R72P (c.412 C>G) polymorphism in heterozygous state (Fig. 
4.1.B),  and 3 out of 33 (9.1%) were homozygous for the codon P72 (c.412 C, the wild-type form) (Fig. 
4.1.C). Sample 8T homozygous for the P72, and sample 11T homozygous for the R72 were heterozygous 
for polymorphisms c.305 G>A and c.836 A>G, respectively identified in the same amplicon. 4T and 7T 
samples heterozygous for the R72P,  were heterozygous for the c.305 G>A and the c.836 A>G 
polymorphism, respectively (Table 4.1). 
 
 
Figure 4.1. Polymorphism at codon 72 of the p53 protein. The chromatograms show  the polymorphisms at 
codon 72 of p53 (red arrows), R72 (A) and P72 (C) in homozygous state, and R72 P (B) in heterozygous state. 
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Table 4.1. Histological type, tumor grade, pT, pN, p53 mutations and polymorphisms of patient samples 
Samples Histological type Grade pT pN p53 mutations p53 polymorphisms 
3T IDC 2 1c X 
  
R72P 
4T IDC 2 1c 0 sn 
  
R72P 
            c. 305 G>A p.P36 in heterozygous state 
5T IDC 2 1c 0 
  
R72P 
            c. 836 A>G p. R213 in heterozygous state 
7T IDC 3 2 0 
 
c.775A>G R72P 
          p.193H>R   
8T IDC 2 2 X 
  
P72 
            c. 305 G>A p.P36 in heterozygous state 
11T IDC 2 1b X 
  
R72 
            c. 836 A>G p. R213 in heterozygous state 
12T IDC 3 X 3a 
 
c.910A>T P72 
          
p.238C>F 
  
16T IDC 3 X X 
  
R72P 
18T ILC 2 X X 
  
R72 
20T IDC            X X X 
 
c.781T>C R72 
          p.195I>T   
23T IDC 2 2 X 
  
P72 
26T IDC 2 2 1 sn 
  
R72 
27T IDC 3 1c X 
  
R72P 
29T IDC 3 2 0 sn 
  
R72 
31T ILC 3 2 0 
  
R72 
33T IDC 2 2 0 sn 
  
R72 
35T IDC 2 2 0 
  
R72P 
37T IDC 3 2 1a 
  
R72 
41T IDC 2 1 0 sn 
  
R72P 
43T IDC 3 2 2a 
  
R72 
44T IDC 2 2 1 
  
R72 
47T IDC 2 2 1 mic 
  
R72P 
49T IDC 2 2 1a 
  
R72 
50T IDC 2 2 1a 
  
R72P 
51T IDC 3 2 1a 
  
R72 
53T IDC 2 2 0 ls 
  
R72P 
54T IDC 2 2 1 
  
R72 
55T IDC 2 2 0 
  
R72 
56T IDC 2 2 1a 
  
R72P 
57T IDC 2 2 3 
  
R72 
58T ILC 2 2a 2 
  
R72P 
62T IDC 2 2 0 sn 
  
R72 
63T IDC 2 2 1a 
  
R72P 
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Table 4.1. Histological type, tumor grade, pT, pN, p53 mutations and polymorphisms of patient samples. 
Legend: IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; G1, low-grade; G2, moderate or    
intermediate grade; G3=high grade; X, not evaluated. 
 
4.2 Expression analysis of Tp53 and Otx1 in breast cancer 
Tp53 and Otx1 gene expression levels were analyzed in the wild-type Tp53 (27 ductal and 3 
lobular) human invasive breast cancer samples (table 4.1) by quantitative real-time reverse 
transcriptase PCR (qRT-PCR), using normal breast tissue as control. Tumors showed higher 
levels of Otx1 and Tp53 gene expression compared with the controls, in which we found basal 
levels of expression. Statistical analysis was performed to verify the correlation between these 
values of expression. Tumor tissues showed a correlation coefficient (r= 0,864) significantly 
different from zero (t= 8,412) with probability p= 1,284E
-0,8 
(Fig. 4.2). The correlation between 
Otx1 and Tp53 gene expression was not observed in the normal breast tissue (data not shown). 
 
 
Figure 4.2. Gene expression levels of Tp53 and Otx1 genes in human breast cancer and correlation analysis.  
Gene expression levels of Tp53 and Otx1 genes was detected by qRT-PCR using Taq Man assays (see Table 3.3) in 
human ductal and lobular invasive breast cancers (table 4.1). The samples are in abscissa, and in ordinate there are 
the expression levels of these genes evaluated with the relative quantitative analysis, using the 2
-∆∆Ct
 method.  
 
In the tumors, the presence of the Otx1 protein was confirmed by immunohistochemical (IHC) 
analysis (Table 4.2). We used rabbit anti-OTX2 polyclonal antibody, which also identified 
OTX1, due to amino acid sequence homology between these proteins. Since Otx2 mRNA was 
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not detected in any tumors by qRT-PCR (data not shown), we considered that the observed 
immunoreactivity was specific for the OTX1. We detected nuclear positivity for OTX1 in few 
cases (Fig. 4.3.A), while the majority of the tumors showed OTX1 cytoplasmic localization (Fig. 
4.3.B). In the non neoplastic tissue adjacent to carcinoma the OTX1 protein was localized in the 
nucleus of  some epithelial cells (Fig. 4.3.C).   












 3T 1  20 (++) 
4T <1 neg 
5T neg 5 (+++) 
7T neg 40 (++/+++) 
8T  20 <5 (+) 
11T 20  20 (+)  
12T  2  >50 (+/+++)  
16T  n.e.  n.e. 
18T  n.e.  n.e. 
20T  n.e.  n.e. 
23T  >2 rare (+++) 
26T  <1 <5 (+/++)  
27T  <1  100 (+) 
29T  neg 10 (+) 
31T  neg  100 (++) 
33T  2 80 (+/+++)  
35T  10  20 (+/+++) 
37T  20  40 (+/++) 
41T  <1 40/50 (+/++)  
43T  <1 40 (++/+++) 
44T  20  90 (+/+++)  
47T  30 neg  
49T  1 80  
50T  2  diffuse (++) 
51T  5 diffuse  (++) 
53T  50  (+/++)  5 
54T  10 20/30 (++) 
55T  10 90 (++) 
56T  2/3  neg 
57T  3 60 (++) 
58T  3 90 ( +++ ) 
62T  10 70 (+/++) 
63T  neg 90 (+++) 
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Table 4.2. OTX1 subcellular localization. Legend: *, % of positive cells; +/++/+++, weak/moderate/intense 
immunoreactivity; n.e., not evaluated. 
Figure 4.3. A-C. OTX1 subcellular localization. The immunohistochemistry shows the nuclear localization for the 
OTX1 protein in the sample 53T (invasive ductal breast carcinoma) (A) and cytoplasmic localization in the sample 
27T (invasive ductal breast carcinoma) (B). In the non neoplastic tissue adjacent to carcinoma (29S) the OTX1 
protein was localized in the nucleus of  some epithelial cells (C). 
 
4.3 Molecular interaction between p53 and Otx1 
In order to demonstrate the direct molecular interaction between Tp53 and Otx1 genes we used 
the doxycycline (Dox) inducible tet-on/p53 SaOs-2 cells (Riley T, 2008). Tp53 expression in this 
cell line was induced by adding Dox to the culture medium. The expression of Tp53 at 12, 24, 
and 48 hours (and its absence in control cells), was confirmed by western blot using an anti-p53 
antibody (Fig. 4.4.A). To evaluate Otx1 expression levels, we used qRT-PCR and western blot 
analysis. Both techniques confirmed the expression of the Otx1 gene at the transcriptional (Fig. 
4.4.B) and at the protein level (Fig. 4.4.A), after  induction of p53 (+Dox). The expression of 
Otx1 clearly increased at 12 and 24 hours after the addition of the antibiotic (Fig. 4.4.B), 
according to the expression of Tp53. The western blot analysis demonstrated the presence of the 
OTX1 protein at 48 hours after p53 induction (Fig. 4.4.A). 
               
Figure 4.4.A. Western blot. The p53 and OTX1 proteins were detected in the Dox inducible tet-on/p53 SaOs-2 
cells treated with Dox at 12 h, 24 h and 48 h, using the untreated cells (0 h) and the SaOs2 not transfected as control. 
Figure 4.4. B. qRT-PCR. Increase of Otx1 gene expression levels in Dox inducible tet-on/p53 SaOs-2 cells treated 
with Dox at 12 h and 24 h. qRT-PCR was performed using Taq Man assays (see Table 3.3). In abscissa there are the 
samples untreated and treated with Dox, and in ordinate there are the gene expression levels. 
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To clarify the nature of interaction between p53 and Otx1 we performed an “in silico” analysis of 
an approximate 4.8 Kb CpG island in the 5’ region of the Otx1 gene, looking for p53 regulatory 
sequences in the OTX1 promoter. The CpG island extends from approximate 3.6 Kb upstream of 
the OTX1 transcription starting site (TSS), up to 1.2 Kb downstream to the TSS. The OTX1 
transcript contains five exons: the first two represent the 5’-UTR, while the ATG is located at the 
beginning of the third exon. It is known that regulatory elements could lie inside introns and 
exons of UTR mRNA (Gressner O, 2005); indeed the analysis was extended to include the first 
two exons/introns. Bioinformatic analysis of the region was performed using the MatInspector 
program by Genomatix (Genomatix Software GmbH), looking for the transcription factors with 
core and matrix similarity above 0.8. The “in silico” analysis showed the presence of two putative 
p53 responsive elements (REs). The first is located at -3435 bp upstream the ATG (5’ p53RE), 
with matrix similarity of 0.942 and core similarity of 0.921. The second (3’ p53RE) is located in 
the second intron at +1268 bp downstream the ATG, with matrix similarity of 0.898 and a core 
similarity of 1.0 (Fig. 4.5.A). 
In order to understand if one of these two putative REs represented a functional p53 binding site, 
chromatin immunoprecipitation analysis (ChIP) was carried out. Tet-on/p53 SaOs-2 cells were 
treated with Dox at 12 and 24 hours, using untreated cells as control. Cells were cross-linked, 
lysated and sonicated in order to obtain chromatin fragments of ~700 bp. Total proteins (cross-
linked and not) were extracted and immunoprecipitated using anti-p53 antibody and anti-IgG as 
non-specific control. The immuno-precipitates (IPs) were extracted, and the cross-linking was 
reverted. DNA fragments was purified from proteins, and the sequence containing the two p53RE 
sites (approximately 160-170 bp) in the promoter of Otx1 was amplified by PCR. No PCR 
product was obtained for the 5’p53RE, indicating that this sequence was not the bindig site for 
p53. A positive signal was obtained for the 3’p53RE, at 24 hours from p53 induction. No signal 
was obtained with the immunoprecipitation using IgG, indicating the specificity of the p53 
antibody (Fig. 4.5.B). 
 
These results clearly demonstrated the direct interaction between p53 and the OTX1 promoter 
through the 3’p53RE. Interestingly, the putative functional p53RE is located after the TSS, into 
the transcribed region. 
 




Figure 4.5.A. In silico analysis of the Otx1 promoter. The in silico analysis showed two putative p53 responsive 
elements (REs) in the CpG island: 5’p53RE and 3’p53RE. 
Figure 4.5.B. PCR analysis of the 5’p53RE and 3’p53RE after immunoprecipitation with p53 protein. Left 
panels show  the PCR analysis performed on the 5’p53RE, and right panels show  the PCR analysis performed on 
the 3’p53RE (primers in the table 3.6). The ChIP assay was performed on the tet-on/p53 SaOs-2 cells untreated (1) 
and treated with Dox at 12h (2) and 24h (3.). 1i ,2i and 3i represent the chromatin sonicated after cross-linking 
(positive control), were the positive signal for p53 is detected. 1,2 and 3 represent the chromatin after cross-linking 
and immuno-precipitation with specific antibody anti-p53. The positive signal is detected only in 3’p53RE after 24h 
of Dox administration. The IgG was used as non-specific control. 
 
 
To clarify if the 3’p53RE was able to drive the expression of the Otx1 gene, we cloned 1431 bp 
surrounding this RE in the pGL3 luciferase basic vector (pGL3-Otx1), to be used as minimal 
promoter. Luciferase (Luc) assay was performed by co-transfecting pGL3-Otx1 with increasing 
amounts of Dox/inducible p53 expression vector, from a ratio of 1:1 to 1:10, in the SaOs2 cells. 
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The results indicated that this region was able to drive the Luc transcription, behaving as a 
minimal promoter. We showed that the Luc activity was directly proportional to the p53 
expression (Fig. 4.6). 
All these results lead to the conclusion that Otx1 is one target gene for p53, which can regulate its 
expression through the 3’p53RE.  
 
 
Figure 4.6. Luc assay. Schematic representation of the luciferase (Luc) reporter plasmid (pGL3-Otx1), with the 
3’p53RE cloned up-stream to the Luc gene (left). The graph (right) shows the increase of luciferase activity when 
increasing amount of Dox inducible p53 (from a ratio 1:1 to 1:10) expression vectors are transfected. In abscissa are 
reported the samples co-transfected with pGL3-Otx1 and Dox inducible p53 expression vector. The empty pGL3-
Otx1 vector was used as control.  In ordinate there is the luciferase activity. 
 
4.4 Correlation between Tp53 and Otx1 in  human MCF7 cell lines differentiated with retinoic 
acid 
Retinoic acid (RA), an active metabolite of vitamin A, triggers antiproliferative effects in tumor 
cells, inducing differentiation and apoptosis, and therefore has great potential as an 
anticarcinogenic agent (Hua). Human breast cancer cell lines MCF7, which express p53 wild-
type, are responsive to treatment with all-trans retinoic acid (ATRA). ATRA inhibits cell cycle 
progression in MCF7 cells and increases the expression of Tp53 (Mrass). In order to demonstrate 
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the possible role of Otx1 in tumor cells differentiation, we performed a qRT-PCR assay to 
evaluate the Otx1 and Tp53 gene expression levels in MCF7 treated with ATRA. Drug treatment 
increased levels of both Otx1 and Tp53, confirming the Otx1 activation by p53 during 
differentiation of cancer cells (Fig. 4.7). The increase of both Otx1 and Tp53 in the MCF7 in 
comparison with the untreated control, was statistically significant with t=7,0545 and p=0,0021 
(p<0,01**), and t= 7,2028 and p= 0,0020 (p<0,01**), respectively. 
 
 
Figure 4.7. Increase of Otx1 and Tp53 gene expression levels detected by qRT-PCR in MCF7 cells treated 
with ATRA. In abscissa are reported the MCF7 cells treated and untreated with ATRA, and in ordinate there are the 
expression levels of the Otx1 and Tp53 genes. 
 
4.5 The p53 family in Otx1 activation 
p53, p63 and p73 are a family of transcription factors, that play a pivotal role in the control of the 
cellular response to DNA damaging agents. p53, Tap73 and Tap63 have proapoptotic function 
while ∆Np73 and ∆Np63 play anti-apoptotic roles (Lonza M, 2006). Tp73 and Tp63 isoforms 
are able to bind to p53RE on the target genes. To verify if p63, p73 and their isoforms were able 
to transactivate the Otx1 gene, through the p53RE, a Luc assay was performed. SaOs2 cell lines 
were co-transfected with Dox inducible tet-on/TAp63α, /∆Np63α, /TAp73α, /∆Np73α 
expression vectors and pGL3-OTX1 vector. We showed that only TAp73α was able to 
transactivate Otx1. (Fig. 4.8). 
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Figure 4.8. Luc assay performed with pGL3-Otx1 and Dox inducible p53, TAp63α, ΔNp63α, TAp73α and 
ΔNp73α expression vectors. In abscissa are reported the samples co-transfected with pGL3-Otx1 and the Dox 
inducible expression vectors. The empty pGL3-Otx1 vector was used as control.  In ordinate there is the luciferase 
activity. 
 
4.6 Role of Otx1 and p53 family in mammary gland development 
Unlike most mammalian organs, which develop primarily embryonically with a more or less 
linear progression toward functional maturity, development of the mammary gland is primarily 
postpuberal and may divided into both linear and cyclical phases (pregnancy, lactation and 
involution) (Lewis MT, 2000). In every stage of mammary development are activated different 
pathways, that regulate cell proliferation and organ remodeling. A qRT-PCR assay was 
performed to evaluate changes in Otx1 (Fig. 4.9.A), Trp53 (Fig. 4.9.B), Trp73 (Fig. 4.9.C) and 
Trp63 (Fig. 4.9.D) gene expression in linear and cyclical mammary gland development in mice. 
Mammary tissues from virgin female CD1 mice 1 month old and 8 months old, and from female 
CD1 mice at 2 weeks of pregnancy, at 2 weeks of lactation and in regression, were obtained. 
RNA was extracted and retro-transcribed, and cDNA was analyzed by qRT-PCR, using the gene 
expression level of virgin 1 month old as control 
The Otx1 expression levels increased in lactation (t=5,4393, p=0,0055-p<0,01**) and in 
regression (t=8,1336, p=0,0012-p<0,01**). Trp73 and Trp63 also increased in lactation 
(t=2,4238, p=0,048-p<0,05*; t=4,7616, p= 0,0089-p<0,01**, respectively) and in regression 
(t=8,9239, p=0,0009-p<0,01***; t=27,0131, p=0,0001-p<0,01***). Instead, Trp53 expression 
levels increased only in pregnancy (t=8,5622, p=0,0010-p<0,01**).  
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These data showed that the Otx1 expression in mouse mammary gland development is 









 Figure 4.9.A-D. Gene expression levels of Otx1 (A), Trp53 (B), Trp73 (C) and Tr63 (D) genes during the 
linear and cyclical (gestation, lactation, involution) development of adult mice mammary gland. The gene 
expression levels were detected by qRT-PCR.  The mice virgin 1 month (mth) old were used as control. In abscissa 
are reported the development stage of the mammary gland, and in ordinate there are the gene expression levels in 
these samples. 
 
4.7 Otx1, Trp63 and Trp73 expression in p53 knock-out mouse in lactation 
In order to confirm the regulation of Otx1 by p53 family members, we evaluated RNA levels of 
Otx1, Trp73 and Trp63 in breast tissues derived from p53-deficient mice at 7 days of lactation by 
qRT-PCR. Donehower and coworkers in 1992 generated the mouse strain carrying a germline 
mutation in the Trp53 gene. The neo cassette replaced a part of the Trp53 intron 4 and the 5’ 
portion of exon 5, deleting approximately 40% of the Trp53 coding region, resulting in the lack 
of the p53 protein (Donehower LA, 1992). In these mice we showed the statistically significant 
increase of Otx1 (t=11,1879, p=0,0004-p<0,01***), Trp73 (t=6,6875, p=0,0026-p<0,01**) and 
Trp63 (t=14,4135, p=0,0001-p<0,01***) gene expression in lactation. We confirmed also the 
absence of the Trp53 expression. All the data were referred to virgin female 1 month old (Fig. 
4.10). 
We demonstrated that in physiological conditions Otx1 regulation was independent from Trp53, 
but it was related to Trp73 and Trp63. 
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Figure 4.10. Gene expression levels of Otx1, Trp63, Trp73 and Trp53 in p53 knock-out mice in lactation. The 
p53 knock-out mice was generate carrying a germline mutation in the Trp53 gene. The neo cassette replaced a part 
of the Trp53 intron 4 and the 5’ portion of exon 5, deleting approximately 40% of the Trp53 coding region, resulting 
in the lack of the p53 protein. The gene expression levels were detected by qRT-PCR. The p53 wild-type mice 
virgin 1 mth old were used as control. In abscissa are reported the samples obtained from the p53 knock-out and the 
virgin mice, and in ordinate there are the gene expression levels. 
 
 
4.8 Otx1 and Tp53 family in differentiation of breast cancer stem cells 
Mammary gland LA7 cells, isolated by rat mammary adenocarcinoma Rama-25 cell line, are 
cancer stem cells (CSCs), with self-renewal properties. They have the capacity to differentiate 
into all of the cell lineages of the mammary gland, and to form heterogeneous tumors and 
metastasis in non obese diabetic-severe combined immunodeficiency (NOD-SCID) mice. LA7 
cells treated with differentiating agents, such as DMSO, are able to form hemispherical polarized 
dome-shaped structures. These structures recapitulate the cellular changes occurring during the 
mammary gland development in pregnancy (Zucchi I, 2007). We analyzed by qRT-PCR the 
relation between Otx1, Trp53, TAp63, ∆Np63 and Trp73 expression levels in LA7 cells and in 
LA7 differentiated (LA7D) with DMSO. We identified a statistically significant increase of Otx1 
(t=8,4280, p=0,0138-p<0,05*), Trp73 (t=2,1465, p=0,0391-p<0,05*) and Trp53 (t=2,7924, 
p=0,0315-p<0,05*) in LA7D, compare to LA7, suggesting the role of these genes in the 
differentiation of cancer stem cells. While, ∆Np63 (t=106,4729, p=0,0001-p<0,01***) showed a 
statistically significant decrease of expression (Fig. 4.11). 
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IHC performed with anti-OTX1 antibody, showed cytoplasmic and nuclear  positivity for OTX1 
in the LA7 cells, with an increase of cytoplasmic positivity in LA7D (data not shown). 
 
 
Figure 4.11. Gene expression levels of Otx1, Trp53, Trp73, TAp63 and ΔNp63 in LA7 cells undifferentiated 
and differentiated (LA7D) with DMSO. The gene expression levels were detected by qRT-PCR. The LA7 cells 
was used as control. In abscissa are reported the LA7 and LA7D cells, and in ordinate there are the gene expression 
levels. 
 
Cells derived from tumors and metastasis generated through the subcutaneous injection of a 
single or few LA7 and LA7D cells, in NOD-SCID mice, were cultured and maintained under 
selective conditions. 
Cell derived from LA7 tumors and metastasis are able to form, in vitro, mammospheres (non-
adherent spherical clusters of stem cancer cells), while those obtained from LA7D tumors and 
metastasis are not (Zucchi I, 2007). 
RNA obtained from these cell cultures, was extracted and retro-transcribed to perform qRT-
PCR.  
We analyzed the expression levels of Otx1 (Fig. 4.12.A), Trp53 (Fig. 4.12.B), TAp63 (Fig. 
4.12.C), ΔNp63 (Fig. 4.12.D) and Trp73 (Fig. 4.12.E). The increase of  Otx1, Trp53 and Trp73 
expression was detected in metastasis and the results were statistically significant.  Interestingly, 
in the tumors induced by LA7D there was the increase of Otx1, Trp53 and Trp73, and the 
decrease of TAp63 and ΔNp63 gene expression levels (Table 4.3). 
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Figure 4.12.A-E. Otx1, Trp53, TAp63, ΔNp63 and Trp73 gene expression levels in LA7 and LA7D, and in cell 
cultures obtained from the tumors and metastasis generated by injection of LA7 and LA7D in NOD-SCID 
mice. The gene expression levels were detected by qRT-PCR. The LA7 cells was used as control. In abscissa are 




     Table 4.3. Statistical analysis 
Gene LA7 tumor LA7D tumor LA7 metastasis LA7D metastasis 
Otx1 NSS t=123,2627 ↑ 
p=0,0001 (p<0,01***) 
t=38,4791 ↑ 
p=0,0007 (p<0,01 ***) 
t=24,9076 ↑↑ 
p=0,0016 (p<0,01**) 







TAp63 NSS t=26,1999 ↓ 
p=0,0015 (p<0,01**) 
NSS NSS 







Trp73 NSS t=48,5834 ↑ 
p=0,0004 (p<0,01***) 
NSS t=4,2181 ↑↑ 
p=0,0419 (p<0,05*) 
 
Table 4.3. Statistical analysis of the gene expression variation in cell cultures obtained from the tumors and 
metastasis generated by injection of LA7 and LA7D, compared to the gene expression in LA7 cells. ↑: increase of 
gene expression level; ↓: decrease of gene expression level. 
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4.9 Otx1 and p53 family in human breast tumors 
The analysis of the expression of Otx1, Tp63, and Tp73 was performed on 32 human breast 
tumor samples (Table 4.4), 22  from the previously described (see table 4.1), and 10 new cases. 
RNA obtained from these Tp53 wild-type breast cancer was retro-transcribed, and qRT-PCR was 
performed using Otx1, Tp63 and Tp73 specific probes. Normal tissue was used as control.  
The variations of Tp63 (Fig. 4.13.B) and Tp73 (Fig. 4.13.C) expression levels respected to Otx1 
(Fig. 4.13.A), was statistically significant, with t=3,1697 and p=0,0024 (p<0,01 **) for Otx1 vs. 
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Table 4.4. Histological type, tumor grade, pT and pN of patient samples 
Samples Histological type Grade pT pN 
3T IDC 2 1c X 
5T IDC 2 1c 0 
8T IDC 2 2 X 
11T IDC 2 1b X 
29T IDC 3 2 0 sn 
33T IDC 2 2 0 sn 
35T IDC 2 2 0 
37T IDC 3 2 1a 
41T IDC 2 1 0 sn 
44T IDC 2 2 1 
47T IDC 2 2 1 mic 
49T IDC 2 2 1a 
50T IDC 2 2 1a 
51T IDC 3 2 1a 
53T IDC 2 2 0 ls 
54T IDC 2 2 1 
55T IDC 2 2 0 
56T IDC 2 2 1a 
57T IDC 2 2 3 
58T ILC 2 2a 2 
62T IDC 2 2 0 sn 
63T IDC 2 2 1a 
64T IDC 2 2 1a 
65T IDC 2 1c 1a 
68T IDC 2 2 1a 
69T IDC 2 2 1a 
70T IDC 2 2 0 (i+) 
71T IDC 2 2 0 
73T IDC 2 1B 0 
74T IDC 2 2 0 
75T IDC 3 2 0 sn 
78T IDC 2 2 1 mi 
 
Table 4.4.  Histological type, tumor grade, pT and pN of patient samples. Legend: IDC, invasive ductal carcinoma; 










Figure 4.13. A-C. Gene expression levels of Otx1, Tp63 and Tp73 in human ductal and lobular invasive breast 
cancers (Table 4.4). The gene expression levels were detected by qRT-PCR using Taq Man assays (see table 3.3). 
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4.10 Statistical analysis between the expression of Otx1, Tp53, Ta63α, ∆Np63α, Ta73α, ∆Np73α 
genes in human breast cancer 
To assess the role of Tp63 and Tp73 in breast cancer, we designed specific primers able to 
recognize TAp63α, TAp73α, ∆Np63α and ∆Np73α isoforms. 
We analyzed the expression levels of Otx1, Tp53 and these isoforms, using normal tissue as 
control (Fig. 4.14.A-F). qRT-PCR showed statistically significant expression variation between: 
Otx1 vs. Tp53, TAp73α, ∆Np63α; Tp53 vs. TAp63α, ∆Np63α, TAp73α, ∆Np73α; TAp63α vs. 
∆Np63α, TAp73α; TAp73α vs. ∆Np63α, ∆Np73α; ∆Np73α vs. ∆Np63α (Table 4.5). ∆Np73 and 
∆Np63 expression are also statistically correlated with linear regression coefficient r=0,87178, 















Figure 4.14. A-F. Gene expression levels of Otx1, Tp53, TAp63(α), ΔNp63(α), TAp73(α) and ΔNp73(α) in 
human ductal and lobular invasive breast cancers (see Table 4.4). The gene expression levels were detected by 
qRT-PCR using specific primers (Sybr Green technology) (see table 3.2). The normal mammary tissue was used as 
control. In abscissa are reported the samples, and in ordinate the gene expression levels. 
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Table 4.3. Statistical analysis of the gene expression variation in breast cancer samples, compared to each other. In 








Genes t value p 
  Otx1/Tp53 4,8693 0,0001 (p<0,01 ***) 
  Otx1/TAp73α 3,3501 0,0014 (p>0,01 **) 
Otx1/∆Np63α 2,6966 0,0090 (p<0,01 **) 
Tp53/TAp63α 7,7407 0,0001(p<0,01 ***) 
 Tp53/∆Np63α 5,2795 0,0001 (p<0,01 ***) 
Tp53/TAp73α 3,6812 0,0005 (p<0,01 ***) 
Tp53/∆Np73α 5,0661 0,0001 (p<0,01 ***) 
TAp63α/∆Np63α 2,5565 0,0130 (p<0,05 *) 
TAp63α/TAp73α 2,8582 0,0058 (p<0,01 **) 
TAp73α/∆Np63α 4,9073 0,0001 (p<0,01 ***) 
TAp73α/∆Np73α 4,0867 0,0001 (p<0,01 ***) 
∆Np73α/∆Np63α 2,0280 0,0469 (p<0,05 *) 
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5 DISCUSSION 
5.1 Tp53 mutations and polymorphisms: cancer implications 
Breast cancer, one of the most common and feared cancers, ranks second after lung cancer 
among tumor-related death (Ries S, 2000). Indeed, one out of nine women is affected in her life 
span by breast cancer, and the current therapies for the disease are inadequate once it has 
metastasized. Normal, as well as malignant, growth is regulated by endocrine hormones and by 
local tissues factors, such as polypeptide growth factors. Breast cancers progress as hyperplastic 
ductal and lobular epithelial growth, acquiring progressive genetic changes (including those of 
oncogenes and tumor suppressor genes) leading to clonal outgrowths of progressive malignant 
cells (Papadakis EN, 2000). 
The Tp53 tumor suppressor gene is commonly altered in human cancer and the spectrum of its 
mutations in these cancers provide clues to the etiology and molecular pathogenesis of neoplasia 
(Papadakis EN, 2000). Tp53 is a key player in stress responses that preserve genomic stability, 
responding to a variety of insults including DNA damage, hypoxia, metabolic stress and 
oncogene activation. The most well documented mechanism by which p53 exercises its 
protective roles is as a transcription factor. By binding to specific response elements in DNA, 
p53 modulates the transcription of genes that govern the major defenses against tumor growth, 
which include cell cycle arrest, apoptosis, maintenance of genetic integrity, inhibition of 
angiogenesis and cellular senescence. p53 also interacts with numerous cellular proteins, 
including several that control programmed cell death, and these molecular interactions might 
contribute to the inhibitory role of p53 in tumorigenesis (Whibley C, 2009). 
Malfunction of the p53 pathway is an almost universal hallmark of human tumors. Somatic 
mutations of Tp53, that result in the absence or dysfunction of p53, are one of the most common 
mechanisms by which the p53 pathway is damaged during tumorigenesis. The direct loss of 
function of p53 is also associated with an unfavorable prognosis in some types of cancer. The 
most common mutations in Tp53 are single base substitution, which result in amino acid 
substitution (missense mutations) in the DNA binding domain (DBD) of the p53 protein. 
Typically, the mutant tumor-associated p53 proteins have lost most or all of the normal p53 
wild-type functions. p53 mutant exert a dominant-negative action toward wild-type p53 
(Whibley C, 2009). In the Tp53 mutations database it is reported that this gene is mutated in 20% 
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cases of breast cancer (Fig. 5.1) (IARC TP53 mutations database), but in our study we found 
9,1% of Tp53 mutated in ductal and lobular invasive breast carcinomas (see table 4.1). 
 
 
Figure 5.1. Percentage of Tp53 mutations in human cancer (IARC TP53 mutations database). 
 
 
The loss of function of p53 is obtained by several other mechanism, including polymorphisms at 
single nucleotide (SNPs), at the Tp53 locus (NCBI SNP database).  Nevertheless, most of these 
variations (80%) are intronic and can be presumed to have no cancer related biological 
consequences (Whibley C, 2009). The remaining 20% are exonic. Of the 19 exonic 
polymorphisms that have been reported in Tp53, 8 of them are synonymous. Although these 
polymorphisms do not change the amino acid sequence or structure of the protein, changes in 
base sequence could modify protein expression, folding and function, or provoke new splicing 
events. The remaining 11 polymorphisms in Tp53 are non-synonymous, resulting in an amino 
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acid change in the protein. Changes in the amino acid sequence can alter the ability of the p53 
protein to bind  to responsive elements (REs) of target genes, alter the recognition motifs for 
post-translational modifications, or alter the protein stability and the interactions with other 
proteins. 
In our work, in 2 human ductal breast cancers (4T and 8T) we found a silent exonic 
polymorphism at codon 36 (CCG to CCA) (see table 4.1), which is located in the region crucial 
for the MDM2 binding. MDM2 is a key negative regulator of p53, which binds to the TA 
domain of p53 and ubiquitylates the protein, targeting it for degradation  in the proteasome. 
Because p53 transcriptionally activates MDM2, the expression levels of p53 and MDM2 are 
balanced through a negative feed-back loop, which is altered by an increase in p53 levels 
following stresses such as DNA damage. MDM2 also binds to Tp53 mRNA, controlling the rate 
of  translation (Whibley C, 2009). The finding that MDM2 (negative regulator of p53) binds to 
mRNA and facilitates the translation of Tp53, and that this interaction is abrogated by silent 
mutations in the N-terminal region, suggests a mechanism by which synonymous 
polymorphisms can affect p53 functions (Whibley C, 2009). In other 2 human ductal breast 
cancers (5T and 11T) we found the rare silent exonic polymorphism at codon 213 (CGA to 
CGG) (see table 4.1), which results in the lost of a TaqI site (Carbone D, 1991). 
In each sample we detected the non-synonymous polymorphism at the codon 72, in homozygous 
state (c.412 C p.P72; c.412 G p.R72) or in heterozygous state (R72P) (see Fig. 4.1 and table 4.1). 
This polymorphism causes functional change in the p53 pathway and is involved in 
tumorigenesis (Whibley C, 2009). Residue 72 is located within the proline-rich region, which 
plays an important role in p53-mediated apoptosis and is required for the growth suppression 
activity of p53. This polyproline region is an Src homology 3 (SH3) binding domain. This 
domain is a small non-catalytic domain that has been identified in many signaling proteins, 
regulating protein-protein interactions. The SH3 domain contain the amino acid motif PXXP 
(where P indicates proline and X indicates any amino acid). The P72 of p53 constitutes one of 
the five PXXP SH3 binding motifs defined within this region. 
Sharp ethnic differences in codon 72 allele frequencies have been observed, with a latitude 
gradient in variant frequency from the equator. The P72 allele frequency is approximately 60% 
in diverse African populations, and 30-35% in Caucasian and in Asian populations (IARC Tp53 
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database). The P72 allele appears to be the ancestral allele by comparison with DNA of non-
human primates (Hu W, 2009). 
p53-P72 is structurally different from p53-R72, and this is reflected by its altered electrophoretic 
mobility. p53-R72 migrates more rapidly on gel than p53-P72 (Papadakis EN, 2000). 
Also the functions of these proteins are different. p53-R72 is more efficient in inducing apoptosis 
and suppressing cellular transformation that the p53-P72. The p53-R72 is also more efficiently 
target of degradation for the E6 protein of HPV16, suggesting that individuals homozygous for 
R72 may be at higher risk of HPV-related cervical cancer (IARC Tp53 database). In contrast the 
p53-P72 appears to induce G1 arrest and senescence at high levels 
 Patients homozygous for P72 have poorer survival than those with other genotypes. 
Furthermore, maintenance of the R allele of Tp53 has been associated with reduced disease-free 
and overall survival in breast cancer. A recent study showed that breast cancer patients with the 
P72 genotype were less sensitive to chemoterapy than those with R72 or R72P (Toyama T, 
2007). This chemoresistance is related to the inability of p53-P72 tumors cells to go into 
apoptosis. 
 
5.2 Regulation of Otx1 gene expression by p53 tumor suppressor protein: role in breast cancer 
stem cell differentiation 
In our work we demonstrated that the p53 protein regulates the expression of homeogene Otx1, 
through the 3’p53RE responsive element (p53RE) in tumors (see Fig. 4.5 and Fig 4.6). This 
direct control raises the question of this interaction’s functional role in tumors. 
While the function of p53 in the control of cell cycle checkpoints, apoptosis and senescence has 
been extensively investigated, its role in cellular differentiation is still poorly characterized. 
Nevertheless, it has been shown in several experimental models that wild-type p53 facilitates cell 
differentiation (Matas D, 2004). 
Tp53 gene is conserved from invertebrates to mammals. Homologs of Tp53 have been described 
in many different organisms, such as sea anemone, clams, C. elegans, Drosophila, frogs, 
zebrafish. The existence of homologs of Tp53 gene in lower organisms such as flies and worms, 
which have short life spans and do not acquire cancer as adults, suggests that tumor suppression 
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may not be the original function for p53. There are some evidences for the role of p53 in 
infection disease, in development and in fecundity. One of the stress responses that activate the 
p53 pathway program is the production of nitric oxide, which is commonly made during an 
inflammatory response. This suggests the possibility that p53 is part of the innate immune 
system’s response to inflammation and infections by initiating a program of defenses. 
Alternatively, the evolutionary origin of the p53 protein in lower organisms utilizes its functions 
to protect the germ line from DNA damage mutations. Indeed, in Drosophila and C. elegans, p53 
is most commonly expressed in the germ line cells, and its function is the surveillance of 
damaged germ cells to eliminate defective offspring from the population by apoptosis (Hu W, 
2009). 
In Drosophila and C.elegans the only dividing cells in the adult organism are the germ line cells 
and a few immune cells. The body plan of vertebrates, however, contains many tissues that 
continue to divide throughout lifetime and renew themselves via tissue specific stem cells (SCs) 
(Hu W, 2008). 
SCs are cells with the capacity to self-renewal and to generate daughter cells, which can 
differentiate into multiple cell types that are found in the mature tissue (Cicalese A, 2009). 
These two functions can be accomplished through single asymmetric self-renewing mitotic 
division, in which one progeny retains SC identity, and the other undergoes multiple rounds of 
divisions before entering a postmitotic fully differentiated state (Fig. 5.2.b and d) (Cicalese A, 
2009). The cells that form the intermediates between SCs and terminally differentiated cells are 
usually referred to as progenitor cells, transit cells, and transit amplifying cells. The two cells 
generated by asymmetric division differ markedly in their proliferative potential: the SC remains 
quiescent or slowly proliferating, whereas the progenitor cell divides actively. This ensures the 
production of large numbers of differentiated progeny while maintaining a relatively small pool 
of long-lived SCs (Smalley M and Ashworth A, 2003). The asymmetric division is a particularly 
attractive strategy, which the SCs can use to perpetuate themselves and to generate differentiated 
progeny, maintaining an appropriate number of cells (Morrison SJ and Kimble J, 2006). 
SCs can also use symmetric division, when they are expanding in number during development 
or, in the adult, after tissue injuries during healing and regeneration, to generate two daughter 
cells that are destined to acquire the same fate (Fig. 5.2.a and c). The capacity to divide 
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symmetrically has been observed in the nervous and hematopoietic system (Morrison SJ and 
Kimble J, 2006). 
The asymmetric and symmetric divisions can be used together or separately to produce an 
appropriate number of SCs and/or differentiated daughters (Fig. 5.2.e) (Morrison SJ and Kimble 
J, 2006). 
Recent evidence suggests that symmetric division is necessary for cancer stem cell proliferation, 
and that asymmetric division functions as a mechanism of tumor suppression in Drosophila 
neuroblasts (Gonzalez C, 2007). Notably, some of the genes that control asymmetric cell 
division in flies have an evolutionarily conserved role in the regulation of cell polarity and in 
tumor suppression, suggesting that polarity loss may contribute causally to cancer in mammals 
(Morrison SJ and Kimble J, 2006). Pelicci and coworkers demonstrated that p53 regulates the 
polarity of cell division in mammary stem cells, inducing asymmetric division and cell 
differentiation, while its lost of function leads to the symmetric division, resulting in tumor 
growth. Pharmacological reactivation of p53 in breast cancer SCs correlates with the restoration 
of asymmetric division and tumor growth reduction (Cicalese A, 2009). 
 




Figure 5.2. Stem cells can facultatively use both symmetric and asymmetric divisions. a. Symmetric division in 
the plane of the epithelium generates two morphologically similar stem cells daughters (orange). b. Asymmetric 
division perpendicular to the plane of the epithelium generates one stem cell and one differentiated daughter. The 
asymmetric division predominates during late fetal development, and in the basal layer of the epithelia and in the 
ventricular zone of the brain, in adult. c. During development, symmetric divisions expand the stem-cell pool. d. In 
healthy adults, divisions perpendicular to the epithelial plane typically maintain normal numbers of stem cells and 
differentiated cells in the basal layer of the epithelia and in the sub-ventricular zone of the brain. e. In healthy adults, 
cells can be lost to injury (X). Symmetric divisions are proposed to regenerate additional stem cells, and asymmetric 
divisions to regenerate differentiate daughters. F. Defects in the regulation of the switch between symmetric and 
asymmetric divisions can be involved in cancer formation or in the decrease capacity for tissue repair. 
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In order to verify if the interaction between p53 and Otx1 could have a role in asymmetric 
division and differentiation of breast cancer stem cells, we tested their expression levels in LA7 
cell lines differentiated (LA7D) with DMSO (see Fig. 4.11). The LA7 cells are clonal lines 
derived from the cell line RAMA-25 isolated from mammary adenocarcinoma induced in rat by 
chemicals. These cells are breast cancer stem cells with SCs properties of self-renewal, the 
capacity to differentiate into all of the lineages of the mammary gland, and to form 
heterogeneous tumors in mice from a single cells. LA7 cells spontaneously undergo 
differentiation in vitro by forming hemispherical polarized domes, and this differentiation can be 
strongly promoted by differentiation inducers, such as DMSO. The in vitro dome formation is 
under specific gene regulation, and corresponds to a specific stage in the lobulo-alveolar 
development of the mammary gland occurring during pregnancy. Distinct steps of cellular 
differentiation take place during the terminal differentiation of the alveolar epithelial cells; these 
steps are defined by the sequential activation of genes coding for milk protein. The 
developmental stage of DMSO-induced domes in LA7 may correlate to an early stage of lobulo-
alveolar development during pregnancy that precedes mammary gland terminal differentiation 
(Zucchi I, 2002). 
We found higher levels of Tp53 and Otx1 in LA7D compared to the undifferentiated LA7 cells. 
These data suggest that the activation of Otx1 by p53 in cancer stem cells could represent an 
attempt to force neoplastic cells to differentiate, and this raise the hypothesis that Otx1 could be 
an “tumor suppressor like gene”, involved in the balance between symmetrical and asymmetrical 
division. 
 
5.3 Regulation of Otx1 gene expression by p53 family in differentiation of breast cancer stem 
cells 
The p53 family includes p63 and p73. The p53, p63 and p73 proteins all contain several 
conserved domains: an amino-terminal transactivation (TA) domain, a DNA binding domain 
(DBD), and an oligomerization domain (OD) In addition to these three domains, p63 and p73 
contain in their carboxyl terminus a protein-protein interaction domain known as the “sterile 
alpha motive” (SAM), and a transcription inhibition (TI) domain. The Tp53, Tp63 and Tp73 
genes give rise to multiple protein products resulting from both alternative promoter usage and 
alternative mRNA splicing. They have two promoters: one upstream from exon 1 that generates 
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isoforms containing TA domain, and one intronic that generates amino-terminal truncated 
isoforms (ΔN) that function as dominant-negative inhibitors of the TA isoforms. Furthermore, 
carboxy-terminal splicing generates a variety of TA  and ΔN isoforms, that give rise to additional 
structural and functional diversity (see Fig. 1.22) (Hu W, 2009). 
p53, p63 and p73 show high sequence homology both at the nucleotidic and aminoacidic level, 
even if p63 and p73 are more closely related to each other than to p53. The DBD of p63 and p73 
shows high sequence homology with the p53 DBD, so p63 and p73 can bind to p53RE on the 
target genes (see Fig. 1.21).  
In order to verify if the TAp63α, ΔNp63α, TAp73α and ΔNp73α isoforms are able to bind to 
3’p53RE in the Otx1 promoter, we performed a Luciferase assay. We showed that only TAp73α, 
in addition to Tp53, transactivates Otx1 (see Fig. 4.8). 
p53 and its homologues TAp73α and Tap63α are tumor suppressor genes, guardians of the 
genome, but whereas TAp73α is comparable with p53 in potency in the transactivation and 
apoptosis assays, Tap63α is very weak. One reason for this difference could be that the TI 
domain of TAp63α isoform drastically reduces its transcriptional activity. The TI domain binds 
to a region in the amino-terminal TA of p63, which is homologous to the MDM2 binding site in 
p53, and inhibits the transcriptional activity. Notably, this TI domain is biologically important, 
because patients with deletions in this region have phenotypes which are very similar to patients 
with mutations in the DBD (Moll UM and Slade N, 2004). 
Although Tp63 and Tp73 are the more recently identified Tp53 family members, it appears that 
these genes are ancestral to Tp53 and possibly evolved from a Tp63/Tp73-like gene. Tp63 and 
Tp73, like Tp53, appear to retain their primordial functions in germline surveillance and 
reproduction (Hu W, 2009). Recent studies inspired by developmental functions of Tp63 and 
Tp73 indicate that members of the Tp53 family also cooperate in differentiation control (Stiewe 
T, 2007). 
For example, the p63 protein is involved in the specification and differentiation of squamous 
epithelial cells (Stiewe T, 2007). During development, a single basal layer of primitive 
epithelium initially covers the inner and outer surface of the organism. As embryogenesis 
proceeds, epithelia that will be exposed to mechanical stress progressively acquire new layers of 
suprabasal and differentiated cells which offer better resistance against environmental effects. In 
  92 
 
the adult, the skin epidermis maintain an inner layer of proliferating cells that give rise to 
multiple layers of terminally differentiated cells that continuously reach and are shed from the 
body surface. A key question is how epithelial stem cells retain this self-renewing capacity, 
which is so critical for epidermal integrity. Tp63 is involved in this mechanism. Mice lacking 
Tp63 are severely compromised in their ability to generate epidermis, as well as many other 
types of stratified epithelia. It has been demonstrated that the two principal isoforms of Tp63, 
TAp63α and ΔNp63α, have distinct roles in epithelial development. ΔNp63α is expressed in the 
primitive epithelium, and in the adult its expression persists in the basal layer of the stratified 
epithelium. This isoform is an epithelial progenitor cell marker that maintains epidermal SCs 
self-renewal capacity, promoting cell proliferation. Instead, TAp63α is predominant in the 
suprabasal layer were there are differentiated cells. In conclusion, ΔNp63α governs basal-
epidermal gene expression while its interaction with TAp63 promotes terminal differentiation 
(Blanpain C and Fuchs E, 2007). ∆Np63α maintains the proliferative potential of epithelial 
progenitors, probably regulating symmetric division of SCs. 
Another example, Tp73 is involved in the regulation of SCs differentiation: ΔNp73α isoforms are 
expressed in proliferating cells, whereas TAp73α isoforms are involved in terminal 
differentiation. During nephrogenesis, there is a spatiotemporal switch from ΔNp73 in 
proliferating nephron precursors, to TAp73 in the differentiation domain of the renal cortex 
(Stiewe T, 2007). 
In contrast to apoptosis, differentiation does not eliminate cells from the organism, but rather 
removes cells from the proliferative compartment at the same time as preserving cellular 
integrity and function. By preventing the proliferation of damaged cells, differentiation further 
helps to maintain the genetic stability of the organism. Differentiation therefore adds to the 
spectrum of p53-based cell fate decisions and could contribute to the tumor suppressor activity 
of the Tp53 family (Stiewe T, 2007). 
In our work we demonstrated that Otx1 activation by p53 is involved in the differentiation of 
breast cancer SCs, and that TAp73α is also able to transactivate Otx1 expression. To assess if the 
TAp73α-Otx1 pathway could have a role in cancer SCs differentiation, we evaluated the Otx1 
and Trp73 (rat homologous to human Tp73) gene expression levels in rodent LA7D cells using 
LA7 cells as control. We showed an increase of both Trp73 and Otx1 gene expression, at higher 
levels than Tp53 (see Fig. 4.11). In its role of genome guardian, Tp73, through Otx1 activation, 
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induces terminal differentiation of breast cancer SCs, probably leading to asymmetric division as 
a mechanism of tumor suppression. We hypothesize that both p53 and p73 are involved in cell 
differentiation, but their expression is probably regulated in a temporal and spatial manner. 
Moreover, we evaluated the levels of Trp63α (rat homologous to human Tp63)  isoform. During 
LA7 differentiation, the ΔNp63α RNA levels decrease (see Fig. 4.11), confirming the role of this 
isoform as a stem cell marker.  
 
5.4 Expression pattern of Otx1 and Tp53 family members in the mammary gland during 
pregnancy, lactation, and involution: role in mammary SCs differentiation? 
The mammary gland is one of the few organs that undergoes numerous rounds of proliferation 
and regression throughout adult life. Development of the mammary gland occurs in several 
different stages: it begins in the embryo, progresses after birth, and is completed in the mature 
individual. The full development of the gland proceeds in distinct phases: embryonic, puberal, 
pregnancy, lactation, and involution (Zucchi I, 2002). 
A rudimentary system of small ducts is present in newborn mice. Later, moderate ductal growth 
occurs until puberty, when a more pronounced development of the ducts leads to the formation 
of a ductal tree. In the puberal phase, the growth pattern is characteristically ductal and  few 
alveoli are formed. This process involves an orchestration of hormones, morphogens and growth 
factors. In virgin mice, the parenchyma consists of a highly organized system of ducts with 
terminal end-buds which represent the major sites of ductal growth and give rise to alveolar 
buds. Full alveolar development occurs during pregnancy: during the first half, alveoli increase 
in number and size, and during the second half, the alveoli start to form larger and differentiated 
secretory lobules. Terminal differentiation of alveolar epithelial cells is completed at parturition, 
with the production and secretion of milk (see Fig. 1.10) (Zucchi I, 2002). This epithelial growth 
is sustained by the mammary epithelial SCs (MASCs), which generate proliferating progenitor 
cells, that differentiate into alveolar secretory cells (see Fig. 1.6) (Polyak K, 2007). Finally, the 
end of weaning suppresses lactation and leads to involution of the lobulo-alveolar compartment, 
returning the mammary gland to its non-pregnant state (Zucchi I, 2002). 
Mammary gland functional differentiation occurs with distinct morphological and molecular 
changes of the epithelial cells and allows for the production and secretion of milk. The secretory 
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alveolar cells represent the final cellular state of the differentiation process within the mammary 
gland. These differentiation steps taking place during pregnancy and lactation are defined and 
characterized by the sequential activation of genes encoding for the milk proteins: WDNM1, β-
casein, WAP and α-lactalbumin. In particular, early pregnancy stage is characterized by the 
expression of WDNM1 and β-casein genes, the expression of which increases during alveolar 
proliferation in the second half of pregnancy and during lactation. Late pregnancy and lactation 
are characterized by the additional expression of WAP and α-lactalbumin. LA7D cells, as 
previously described, correlate to early pregnancy stage, because express WDNM1 and β-casein 
genes, but not  WAP and α-lactalbumin (Zucchi I, 2002). The LA7 cells represent a model for in 
vitro differentiation of mammary epithelial cells. 
In LA7D cells we demonstrated that p53, p73 and Otx1 are involved in cancer SCs 
differentiation, with the formation of structures that correlate with lobulo-alveolar differentiation 
at the end of the first stage of pregnancy. To verify if this pathway plays a role during in vivo 
linear and cyclical mammary gland development, we evaluated the Trp53, Trp63, Trp73 (mouse 
homologues to human Tp53, Tp63 and Tp73) and Otx1 gene expression levels in pregnancy, 
lactation and involution, in mice. We showed an increase of Otx1, Trp73 and Trp63 gene 
expression levels in lactation (2 weeks) and in regression, with an increase of Trp53 in gestation 
(2 weeks) (see Fig. 4.9). 
p53 is a potent mediator of pregnancy. In the normal mammary gland of the virgin mouse, the 
p53 protein is expressed at basal levels in the ductal epithelium of the quiescent gland. Under 
hormonal stimulation, which occurs during pregnancy, p53 is translocated in the nucleus of the 
epithelial cells and is activated (Sivaraman L, 2001). We found high Tp53 expression levels at 
half pregnancy, when the alveoli start to differentiate. We hypothesize that p53 could be 
involved in this process, by activating asymmetric divisions of MASCs, and inducing cell 
differentiation. 
During the cyclical development of the mammary gland, in physiological conditions, Otx1 
expression is not regulated by p53, but its expression is correlated with Trp73 and Trp63. To 
confirm this datum we evaluated the Otx1, Trp73 and Trp63 expression in the p53-deficient 
mouse in lactation on the 7
th 
day, and we showed high levels of gene expression (see Fig. 4.10). 
It has been reported that the lactation in p53-deficient mice is normal (Blackburn AC and Jerry 
DJ, 2002). It is known that homeobox genes are involved in the development of mammary gland, 
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regulating proliferation and differentiation of MASCs and progenitor cells (Chen H and Sukumar 
S, 2003). We found that Otx1 is involved in lactation, and we hypothesize that, through 
activation by p73 or p63, it could regulate the terminal differentiation of the MASCs. 
Otx1, Trp63 and Trp73 are also involved in the involution of the mammary gland. This process 
is characterized both by apoptosis of mammary epithelial cells and by tissue remodeling of the 
gland to a duct system similar to that in the mature virgin (Furth PA, 1999). It has been reported 
that OTX1 is involved in the pruning of long distance axonal projections during the development 
of the nervous system. The development of precisely wired neuronal circuits requires that axons 
grow to appropriate targets and form specific patterns of synaptic connections. In many animals, 
during embryonic development, the emergence of the final adult pattern of connectivity is 
preceded by the formation of transient “exuberant” connections.  The OTX1 protein is required 
for the elimination of exuberant projections from neurons in layer 5 of the cerebral cortex. 
(Zhang YA, 2002). We found that OTX1 could exert a similar function during the mammary 
gland remodeling. 
 
5.5 The properties of mammary gland cancer SCs: involvement of p53/p63/p73/Otx1 pathway in 
breast cancer and metastasis formation  
Breast cancer is the leading cause of cancer-related death in women world-wide. Despite 
significant advances in diagnosing and treating breast cancer, several major unresolved problems 
remain, such as tumor progression, recurrence, treatment and therapeutic resistance. Resolving 
these problems is complicated by the fact that breast cancer is not a single disease, but is highly 
heterogeneous at both the molecular and clinical levels (Polyak K, 2007). According to the 
“cancer SCs hypothesis”, tumors are derived from mutated stem cells that have retained, or 
progenitors/differentiated cells that have regained, the SC property of cell-renewal. The cancer 
SCs possess the capacity for indefinite self-renewal, while the lineage of committed progenitor 
cells, have lost this capacity (see Fig. 1.12). Therefore, in tumors there is a heterogeneous and 
complex population of cancer SCs, progenitor cells, transit amplifying cells, and differentiated 
cells (Zucchi I, 2008). 
Rat breast cancer SCs, LA7, can form heterogeneous tumors from a single cell when injected in 
mice. LA7-generated tumors contain at least three distinct cell types: polygonal, epithelial 
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elongated and mesenchyme-like cells, distinguishable by their morphology and expression 
markers. The polygonal and epithelial elongated cells have different properties in term of the 
ability to sustain sphere formation, and the capacity for 3D organotypic growth and in terms of 
tumor-development and tumor-sustaining capacity. The mesenchymal-like cells exhibit limited 
expansion capacity and no capacity to generate sphere and 3D organotypic growth. The 
polygonal cells are self-renewing cancer SCs, and the epithelial cells are lineage-committed 
progenitor cells (Zucchi I, 2008). 
In our work we evaluated the role of Otx1, Trp53, Trp63 and Trp73 in the development of 
tumors and metastasis, after the injection of LA7 and LA7D in mice (see Fig. 4.12).  
A single undifferentiated LA7 cell has the capacity to generate tumors. These tumors contain 
highly proliferating cells, expressing the proliferation marker Ki67, and terminally differentiated 
cells, expressing luminal and myoepithelial markers. They also show partial higher order of 
structural organization, reminiscent to the architecture of the tissue of origin. Cells derived from 
these tumors were cultured and established under selective conditions, obtained removing mouse 
cells and rat tumor differentiated cells (Zucchi I, 2007). Trp53 was over-expressed and ΔNp63 
down-regulated in the established cultures (see Fig. 4.12), indicating the possible Tp53 activation 
to lead to the asymmetric divisions of breast cancer stem cells. 
Tumors derived from LA7D cells retain only a sub-set of tumor-initiating cells. The 
differentiation of multipotent LA7 cells results in a cellular hierarchy in which most cells do not 
contribute to tumor initiation and growth. Cells derived from these tumors do not form 
mammospheres in vitro, and the sphere-forming ability is associated with stem cells (Zucchi I, 
2007). In these committed cells derived from LA7D-tumors we found over-expression of  Otx1, 
Trp53 and Trp73, confirming their role in differentiation. Instead, ΔNp63 and TAp63 are down-
regulated (see Fig. 4.12). 
LA7 and LA7D injected in mice are able to form metastasis. The cancer SCs or the progenitor 
committed cells can migrate from origin tumor, invade a new tissue and undergo metastatic 
growth. These processes allow the neoplastic cells to enter lymphatic and blood vessels for 
dissemination into circulation (see Fig. 1.14). There is diversity in tumor cell migration: the cells 
can migrate as a single cell or as collective cells. Collective movement of cells is a well 
described phenomenon that occurs during embryological development, such as during the 
development of glands and ducts of mammary tissue. In breast cancer highly differentiated, 
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collective cell invasions are described (Friedl P and Wolf K, 2003). Otx1 gene is over-expressed 
in metastasis induced by both LA7 and LA7D cells (see Fig. 4.12). Several experiments in 
zebrafish embryos give rise to the fact that OTX1 is able to induce cell aggregation in embryonic 
development (Bellipanni G, 2009). In the migration process OTX1 could induce cellular 
aggregation of neoplastic cells, and in metastasis OTX1 could activate cell differentiation, under 
p53 and p73 regulation. 
 
5.6 p53/p73/p63/Otx1 network in human breast cancer 
p53, p73 and p63 exhibit significant homology in the DBD and OD. They can bind and 
transactivate the same target genes and form homo/heterotetramers. The ratio between the 
different oncogenic (ΔN isoforms) and anti-oncogenic (TA isoforms) family members is critical 
to direct the balance between life or death following DNA damage (Moll UM and Slade N, 
2004). 
Molecular interaction between TA/ΔN isoforms have been demonstrated both at the 
protein/DNA level and at the protein/protein level (Moll UM and Slade N, 2004). Mixed protein 
complexes are found between ΔNp63/TAp73-TAp63 and ΔNp73/TAp63-TAp73 isoforms, while 
complexes between wild-type p53 and p73 or p63 are not observed. In contrast, mutated p53 
could interact with TAp63 and TAp73 proteins. p53 mutant, ΔNp63 and ΔNp73 isoforms 
generally exert a dominant-negative action toward wild-type p53, TAp63 and TAp73 isoforms 
(Moll UM and Slade N, 2004). 
The interactions between p53 family members are under strict molecular regulation and lead to 
the cellular fate during development or under DNA damage. These interactions are critical to 
maintaining the genome integrity, regulating proliferation, differentiation, senescence or 
apoptosis. Oncogenic stress signals deregulate the cellular ratio between TA/ΔN isoforms in 
favor of the ΔN isoforms which inhibit apoptosis and lead to the proliferation and renewal of 
cancer SCs. On the contrary, differentiation signals shift the balance between TA and ΔN 
isoforms toward the TA isoforms, which regulates the asymmetric division of stem cells (Fig. 
5.3) (De Young MP and Ellisen LW, 2007). 
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Figure 5.3. p53-family-based cell-fate decision. The p53 family is activated by cellular stress, hyper-proliferative 
signals and developmental stimuli. These inputs are integrated within the p53 family in crosstalk with other cellular 
signaling networks to reach an appropriate cell fate decision that is executed by the selective transactivation of 
distinct transcriptional programmes. The most common outcomes are reversible cell cycle arrest, irreversible cell 
cycle exit (differentiation or senescence) or apoptotic cell death. 
 
In human ductal and lobular invasive breast cancer we found over-expression of Otx1, Tp53, 
TAp63α and TAp73α, with down-regulation of ΔNp63α and ΔNp73α (see Fig.4.14.A-F), and 
statistical correlation between Otx1/Tp53 (see Fig. 4.2), and ΔNp63α/ΔNp73α (see Fig. 4.14.G). 
These data suggest that Otx1, Tp53, TAp63α and TAp73α over-expression represent an attempt 
to force the neoplastic cells to differentiate, and this raises the hypothesis that Otx1 could be 
involved in the balance between symmetrical and asymmetrical cell division. 
 
5.7 OTX1 cellular localization: role in the cell differentiation 
In the human ductal and lobular invasive breast cancer we showed the OTX1 cytoplasmic 
localization in the most of samples, while in few samples and in non neoplastic tissue adjacent to 
carcinoma we detected nuclear localization (see Fig. 4.3). In LA7 cells we showed nuclear 
localization, while during the differentiation of LA7 cells we detected an increase of OTX1 
cytoplasmic localization. 
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The OTX1 nuclear and/or cytoplasmic localization suggests different functions of this molecule 
in cell differentiation. During the development there are some examples. It has been reported that 
the subcellular localization of the OTX family members have a role in differentiation during 
embryo development. During the corticogenesis the OTX1 protein is required for the axon 
refinement of the  neurons in the layer 5. OTX1 protein is initially located to the cytoplasm of 
the progenitor cells in the ventricular zone, and remains cytoplasmic up to neurons migrate and 
begin start to differentiate. During the first week of postnatal life, when layer 5 neurons begin 
pruning their exuberant axons, OTX1 is actively imported into the nuclei (Zhang YA, 2002). 
OTX2, a member of the OTX family, is involved in the differentiation of the rods and bipolar 
cells in fetal retina. The subcellular localization of OTX2 is important to determine the fates of 
rod photoreceptor and bipolar cells, during their generation, and initial differentiation in the 
neonatal retina. The segregation of postmitotic cells into immature rods and bipolar cells, under 
the influence of various extrinsic factors, such as retinoic acid, is accompanied by the  OTX2 
localization into cytoplasm and nucleus, respectively (Baas D, 2000). 
We hypothesize that the subcellular localization of OTX1 could be involved in different 
pathways and stages of differentiation. Further studies are need to demonstrated the role of the 
OTX1 cellular localization in the tumors. 
 
5.8 The retinoic acid and breast cancer therapy. Induction of breast cancer cells differentiation, 
through activation of p53, Otx1 pathway. 
We demonstrated that retinoic acid (RA) induces transcription of both Tp53 and Otx1 in breast 
cancer cells. 
RA, a biologically active metabolite of vitamin A, plays a critical role during normal 
development and in the establishment and maintenance of physiological process in adult tissues. 
Its function is induce cellular differentiation, through binding to the two classes of nuclear 
receptors, the retinoid acid receptors (RARs) and the retinoid X receptors (RXRs). RARs and 
RXRs are member of the steroid-thyroid hormone receptors super-family. Both types of retinoid 
receptors are encoded by three distinct genes, α, β, and γ. These receptors function as ligand 
activated transcription factors that bind to specific RA response elements (RAREs) on the target 
genes and regulate their expression. The ligand-binding domains (LBDs) of RARs and RXRs are 
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distinct, and can be pharmacologically targeted separately. The RARE sequence consists of 
AGGTCA or like core motifs arranged as a direct repeat with 2 or 5 bp spacing (Lee MO, 1995). 
RARs can heterodimerize with RXRs, whereas RXRs also heterodimerize with other nuclear 
hormone receptors, including thyroid hormone receptors or vitamin D receptors. In absence of 
ligands for the RAR-RXR complex, the target genes of the receptors are repressed. This is due to 
the recruitment of complexes containing  histone deacetylases (HDAC) and co-repressors. This 
process results in histone deacetylation, chromatin compaction and silencing of target gene 
promoter regions. After binding with ligands, such as RA, the retinoid receptors are activated. 
RA dissociates HDAC-containing co-repressor complex and recruit co-activator-histone 
acetyltransferase (HAT) complex. The final result is chromatin decondensation and 
transactivation of target gene promoter, involved in cell differentiation or apoptosis (Jimenez-
Lara AM, 2004). 
Data from animal models, epidemiology, preclinical and clinical trials have provided strong 
support for the use of retinoic acids as pharmacological agents in cancer therapy and prevention. 
Certain malignancies, such as acute promyelocytic leukemia (APL), juvenile chronic 
myelogenous leukemia, Kaposi’s sarcoma and high-risk neuroblastoma, are already being treated 
with retinoid-based therapies. In addition, retinoids can be use in psoriasis and acne therapy, and 
prevent the development of non-melanoma skin cancer in patients with defects of DNA repair, 
such as xeroderma pigmentosus (Table 5.1) (Jimenez-Lara AM, 2004). 
 
Table 5.1. The clinical use of retinoids in cancer therapy and chemoprevention 
 
The pleiotropic actions of retinoids and their ability to force cells into differentiation and death, 
offer great promise for cancer therapy and chemoprevention. Following the success of RA in 
differentiation therapy for APL, interest has increased in the potential use of retinoids for the 
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prevention and treatment of human breast cancer and other solid tumors (Stephen R and Darbre 
PD, 2000). The problem is that long-exposure to RA can induce cell-resistance, so the clinical 
applications of RA have shown limited effects. A possible solution is combine retinoids with 
other therapies, such as chemoterapy, interferons, or anti-estrogens in estrogen (E)+/RAR+ 
patients (Hua S, 2009). 
Expression of RARα receptors have been found at high levels in ER positive breast cancer cells. 
There are several reports that RARE are coincident with E receptor responsive elements (EREs) 
in the promoter of target genes (Stephen R and Darbre PD, 2000). Estrogen receptors (ERs) are a 
member of the steroid-thyroid hormone receptors super-family, like RARs. Many of the genomic 
regions bound by RARs overlapped with ERs (Fig. 5.2). Transcriptional analysis demonstrated 
that RARs and ERs have agonistic effects in the transcription of target genes. While RA induces 
cell differentiation and apoptosis, E signaling drives proliferation and promotes survival in cell 
lines (Hua S, 2009). Furthermore, it has been demonstrated a feed-back between RAR/ER 
transcription. E can up-regulate expression of RAR, while RA can down-regulate ER expression, 
suggesting a two-way interactive regulatory pathway. This highly coordinated intersection 
between RAR/ER signaling pathway, provides a global mechanism for balancing gene 
expression (Stephen R and Darbre PD, 2000). 
 
 
Figure 5.4. Schematic representation of the retinoic acid receptor responsive element (RARE) and estrogen 
receptor RE (ERE). Retinoic acid receptors and estrogen receptors are members of the steroid-thyroid hormone 
nuclear receptors super-family. They bind to the specific REs on the target genes. The ERE is a perfect inverted 
hexanucleotide repeat, while RARE is an imperfect hexanucleotide repeat. All hexanucleotides have the general 
sequence AGNNCA. The central  two nucleotides confer  the binding specificity. 
In breast cancer cells, the RA has been shown to be associated with down-regulation of several 
genes essential for proliferation and survival, and with up-regulation of genes involved in cell 
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differentiation and apoptosis, such as Tp53. While RAR increases the Tp53 expression (Mrass P, 
2004), ER inhibits the p53 functions (Konduri SD, 2010). Several lines of evidence suggest that 
p53 and ERα can influence each other activities through different mechanisms. Complexes 
between p53 and ERα proteins have been described, with inhibitions of p53 activity. ERα can 
also control p53 mRNA expression, and vice versa, and p53 can down-regulate ERα responsive 
genes by interfering with the binding of ERα to its EREs (Fernandez-Cuesta L, 2010). 
The identification of the genes regulated by RARs in breast cancer cells, and in particularly the 
discovery of their extensive crosstalk with estrogen signaling, may benefit breast cancer 
diagnostics and therapeutic intervention. Specifically, RARs and ERs can diagnostically 
differentiate tumor subtypes and patient outcome. The Luminal type breast tumors show high 
expression of direct target genes of ERs and RARs, indicating that their antagonistic affects may 
be relevant for primary ER-positive tumors. The expression of RAR targets genes, predicts a 




In our work we demonstrated that the Otx1 homeogene is over-expressed in human ductal and 
lobular invasive breast cancer. The p53 and TAp73α tumor suppressor proteins transactivate the 
Otx1 gene in the tumors. This pathway is involved in the differentiation of LA7, leading to the 
asymmetric division of the breast cancer stem cells in a spatial and temporal manner.  
LA7 cells are a model for the study of mammary gland development. LA7 differentiated with 
DMSO form dome-structures that corresponds to a specific stage in the lobulo-alveolar 
development of the mammary gland occurring during pregnancy. 
During the adult linear and cyclical (pregnancy, lactation, involution) mammary gland 
development the Otx1 expression is not regulated by p53, but is correlated with Tp73 and Tp63 
gene expression in lactation and in regression. This suggests that Otx1 gene is regulated by p73 
in physiological conditions, but in the tumor is involved p53. Needs to clarify the role of p63. 
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5.10 Perspectives 
The relation between p63 and Otx1 is unclear. The Luc assay has shown that the p63 isoforms 
are not able to transactivate the Otx1 expression, but during physiological mammary gland 
development the Tp63 expression increases whit Otx1. The question is which is the target gene.  
The p63 protein regulates the Otx1 gene, or the OTX1 protein regulates the Tp63 gene? 
Preliminary studies to identify down-streams of OTX1 were carried out using a computational 
approach based on the alignment of the conserved OTX1 binding sites between mammalian 
species (Orso F, 2010). The analysis found an OTX1RE in the Tp63 promoter in a non-canonical 
region in the intron 4. To confirm the molecular interaction between OTX1 and Tp63 promoter, 
Chip and Luc assay will be performed. 
The same approach will be used to found retinoic acid responsive elements and estrogen 
responsive elements on the Tp53 promoter. The molecular mechanisms by which RARs/ERs 
regulate Tp53 expression are still unclear. It has been reported that these receptors regulate 
indirectly the Tp53 expression (Fernandez-Cuesta L, 2010)(Mrass P, 2004), but the presence of 
RAREs/EREs in the promoter of Tp53  has not been found yet. We demonstrated that RA 
increases the expression of both Tp53 and Otx1 genes, with differentiation of breast cancer cells 
as result, but the molecular activation of these pathway will be demonstrated. Furthermore we 
will look for RAREs and EREs in the other members of the p53 family. 
p53 is hormonally responsive, activated by estrogen and progesterone during pregnancy 
(Sivaraman L, 2001). We will study the effects of the estrogen and progesterone on the 
mammary stem cells and LA7 breast cancer stem cells, evaluating if these hormones activate the 
Otx1, p53, p63, p73 pathway, at level of both mRNA and protein.  
Simeone A. demonstrated that Otx1 directly activates the growth hormone (GH), follicle-
stimulating hormone (FSH) and luteinizing hormone (LH) transcription in the anterior lobe of 
the pituitary gland (Acampora D, 1998). Furthermore p53 nuclear accumulation was found in 
corticotroph adenomas (Kontogeorgos G, 1999). We will evaluate the correlation between Otx1, 
Tp53,Tp63 and Tp73 in pituitary adenomas and in normal adenohypophysis to demonstrate the 
role of the hormones on the Otx1, p53, p63, p73 pathway. 
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